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Cystic fibrosis (CF) is an autosomal recessive disorder affecting 70,000 individuals 
worldwide.  This disease is characterized by the buildup of mucus in the airways leading to 
chronic lung infections resulting in pulmonary failure and death in 95% of CF patients.  Routine 
surveillance of CF pathogens using traditional microbiology culture guides management and 
treatment of CF patients.  Molecular profiling studies have revealed emerging pathogens that 
may play a role in CF lung disease by either directly causing infection or upregulating the 
virulence factors of classic CF pathogens, such as P. aeruginosa; however, routine CF culture 
protocols have not been modified to detect these organisms.  The goal of this study was to 
expand the data relevant to the use of microbiology cultures for the management and treatment 
of CF patients at Virginia Commonwealth University Medical Center (VCUMC) by directly 
selecting for emerging CF pathogens in culture.  This was accomplished by developing, 
   
optimizing, and implementing an agar to select for colistin-resistant non-fermenting Gram- 
negative rods (NF GNRS).  In addition, McKay agar and anaerobic media were utilized to 
recover members of the Streptococcus anginosus group (SAG) and anaerobes in CF respiratory 
samples.  The prevalences of SAG, anaerobes, and colistin-resistant NF GNRs recovered on 
study media from 75 adult and pediatric CF patients at VCUMC were 17.33%, 41.33%, and 4% 
respectively.  Approximately 62% of patients culture-positive for SAG were also infected with 
P. aeruginosa and 53.8% of SAG recovered in culture were from CF patients experiencing PE.  
These findings further support the claim that interspecies interactions among emerging and 
classic CF pathogens may result in periods of clinical instability or PE.  Twenty-eight of the 75 
patients were culture-positive for Veillonella species, with the majority of samples collected 
during a period of surveillance.  Four colistin-resistant NF GNRs were isolated on the study 
media alone.  The selective nature of the study media prevented the mixed respiratory flora and 
classic CF pathogens from overgrowing and obscuring the growth of these colistin-resistant NF 
GNRs.    The presence and role of emerging pathogens in the CF patient population at VCUMC 
warrants further investigation; therefore, the routine culture protocol needs to be revised to 
recover and select for those organisms thought to play a role in PE and lung function decline. 
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Chapter 1:  Introduction 
 
 Cystic fibrosis (CF) is an autosomal recessive disorder that affects the lungs and digestive 
system of approximately 70,000 individuals worldwide.  Thirty-thousand of those diagnosed 
with CF reside in the United States (US) and more than 10 million Americans are carriers of one 
mutation of the CF gene.  The number of people who carry a CF gene mutation based on race is 
as follows:  1 in 29 Caucasian Americans, 1 in 46 Hispanic Americans, 1 in 65 African 
Americans, and 1 in 90 Asian Americans.  Based on this data and the autosomal recessive 
inheritance pattern, approximately one in every 3,000 Caucasian newborns have CF (CF 
Foundation, www.cff.org).  Virginia Commonwealth University Medical Center (VCUMC) 
houses adult and pediatric CF programs, both of which are accredited by the CF Foundation 
(CFF).  Combined, these programs follow 63 pediatric and 90 adult CF patients in Central 
Virginia (VA) and neighboring areas. 
 To date more than 1,800 CF gene mutations have been described (CF Foundation, 
www.cff.org). Mutations in the CF transmembrane conductance regulator (CFTR) gene result in 
abnormal transport of chloride and sodium across epithelium, leading to the production of thick, 
sticky mucus that may clog the lungs and obstruct the pancreas (Simon, 2009).  Decreased 
mucociliary clearance leads to chronic pulmonary infections.  Throughout the course of the 
disease, CF patients experience episodes of acute pulmonary exacerbations (PE) which 
eventually lead to irreversible lung damage.  A universal definition of PE does not exist 
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among clinicians; however, it is agreed that PE is characterized by increased respiratory 
symptoms and worsening lung function (Zemanick et al., 2013; Sibley et al., 2008). 
 Progressive lung function decline is the primary cause of morbidity and mortality in the 
CF population.  The median predicted survival of CF patients is 41 years.  Treatment approaches 
consist of chronic suppressive antimicrobial therapy in addition to aggressive antibiotic regimens 
during periods of acute PE (LiPuma, 2010; CF Foundation, www.cff.org).  Respiratory cultures 
from CF patients indicate early colonization of the lungs most commonly with Staphylococcus 
aureus, typically followed by Pseudomonas aeruginosa.  Due to phenotypic changes within the 
lung, P. aeruginosa often transitions to a mucoid strain, which is common in CF patients.  
Mucoid P. aeruginosa strains are very drug resistant and almost impossible to eradicate (Waters, 
2012).  Later, patients can be colonized with members of the Burkholderia cepacia Complex 
(BCC).  This is associated with advanced disease and poor patient outcomes (LiPuma, 2010).  
All of the above listed organisms are considered to be the classic CF pathogens. 
 As a result of molecular profiling studies, emerging pathogens have been increasingly 
recognized in the CF population (Zhao et al., 2012; Armougom et al., 2009; Rabin and Surrette, 
2012; Sibley et al., 2011).  These are defined as organisms found in CF respiratory samples that 
are not part of the canonical or classic list of pathogens.  Several possible reasons exist for the 
increase in emerging pathogens including increased use of antibiotics, identification of pathogens 
with selective media and molecular methods, and increased surveillance.  In the past 10 years, 
the life span of CF patients has risen which, in turn, is associated with an increased use of 
antibiotics.  Incorporation of selective media for BCC isolates has caused phenotypically similar 
organisms such as Ralstonia and Pandoraea to be recovered in culture.  Molecular methods, 
such as multilocus sequence typing (MLST) and pyrosequencing, are often used to characterize 
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the microbial epidemiology of CF respiratory samples and have the ability to detect a wide 
variety of organisms that are uncultivable or simply not selected for using the current CF 
microbiology protocol.  Frequent surveillance is also associated with an increase in emerging 
pathogens (Miller and Gilligan, 2003); CF patients are typically monitored on a quarterly basis.  
The role of emerging pathogens in CF lung disease is poorly understood.  Investigating the 
presence of these potential pathogens in culture is the first step in trying to determine their 
association in CF lung disease. 
 Molecular profiling studies of CF patient samples revealed the presence of oral flora and 
anaerobes in the lung suggesting that they may play a significant role in CF lung disease.  
Historically, these organisms have not been considered pathogens; however, they are present in 
equal or greater quantities than the principal or classic pathogens.  Members of the Streptococcus 
anginosus Group (SAG), formerly known to as the Streptococcus milleri group (SMG), have 
been associated with PE and lung function decline.  SAG consists of Streptococcus constellatus, 
Streptococcus anginosus, and Streptococcus intermedius, which exist as normal flora in the 
oropharynx and gastrointestinal (GI) tract in approximately 15-30% of the population (Parkins et 
al., 2008).  Their presence in CF respiratory samples has been overlooked and attributed to 
oropharyngeal contamination acquired through the specimen collection process.   
Current CF microbiology protocols do not select for SAG.  Using the prescribed battery 
of media, SAG are often overgrown by principal pathogens such as P. aeruginosa.  In addition, 
they are phenotypically indistinguishable from other nonpathogenic Streptococcus species.  
Sibley et al. (2010) developed and incorporated a semi-selective solid medium, McKay agar, to 
select for SAG.  A six-month surveillance study revealed that SAG had a prevalence of 
approximately 40% in the population studied.  In another study conducted by Sibley et al. 
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(2008), molecular methods identified SAG as the numerically dominant organism in a group of 
hospitalized adult CF patients experiencing acute PE, strongly suggesting association of this 
organism group with clinical deterioration.  Notably, when this group of organisms was targeted 
for therapy, resolution of symptoms was observed and baseline lung function restored even in the 
absence of anti-pseudomonals.  Waite et al. (2012) reported on the ability of SAG to proliferate 
within the lung prior to and during the onset of PE, indicating that this group could potentially 
represent a microbiologic marker of exacerbation. The increasing recognition of SAG as a key 
player in the microbial community of the CF lung as well as its reported ability to cause acute 
exacerbations in this specified population of patients warrants the need for routine isolation and 
identification in culture (Waite et al., 2012; Filkins et al., 2012).  
 Hypoxic conditions in the CF lung provide a favorable environment for anaerobes, 
though their role in the disease process is unclear.  Animal lung models have shown that certain 
anaerobes have the ability to become cytotoxic and immunogenic in high quantities (Zemanick et 
al., 2013).  Others have reported the ability of anaerobic bacteria to enhance the virulence of 
classic CF pathogens such as P. aeruginosa (Field et al., 2010).  Currently, CF respiratory 
culture protocols do not include anaerobic media or incubation conditions.  Specifically targeting 
anaerobes in culture could aid in determining their role in CF lung disease. 
 Selecting for glucose non-fermenting Gram-negative rods (NF GNRs) in culture by 
incorporating additional media has led to the emergence of other, previously unrecognized NF 
GNRs, which often exhibit multidrug resistance.  For example, selective media for members of 
the BCC, is part of the routine battery of culture media.  Phenotypically similar NF GNRs, with 
multidrug resistant susceptibility profiles, grow on this media as well.  This can lead to 
misidentifying organisms such as Ralstonia or Pandoraea as BCC, a confirmed and widely 
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recognized CF pathogen, which has great clinical and psychosocial implications for the patient.  
Because members of the BCC are considered epidemic strains, infection control measures of 
culture-positive patients must be followed.  BCC culture-positive CF patients are often isolated 
or physically separated from those who are BCC-negative.  In addition, acquisition of BCC is 
often associated with more severe disease and worsening lung function.  Before selective BCC 
media was added to routine CF culture protocols, the presence of emerging NF GNRs in clinical 
samples was not detected.  Due to extremely resistant susceptibility patterns, particularly to 
colistin, their role in CF lung disease needs to be determined.  Colistin is frequently used as the 
last line of defense when treating multidrug resistant P. aeruginosa infections and also in efforts 
to help prevent the establishment of chronic infections in the lung.  As a result, Kiska and 
Riddell (2012) suggested fully identifying any colistin-resistant NF GNRs isolated in CF 
samples.  Therefore, development and incorporation of media selecting for colistin-resistant NF 
GNRs is warranted to further recognize their presence in respiratory samples and determine their 
role in CF lung disease. 
 Inquilinus limosus is a NF GNR associated with CF lung function decline.  This organism 
has a mucoid phenotype and either grows poorly or fails to grow on MacConkey agar (MAC).  I. 
limosus can grow on Blood agar (BA) and Chocolate agar (CHOC); however, the colony 
morphology is identical to that of mucoid P. aeruginosa.  Since many CF patients harbor strains 
of mucoid P. aeruginosa, I. limosus is not recognized as an additional NF GNR in culture, and 
could potentially be overlooked. Distinguishing between the two organisms is imperative for 
treatment purposes.  Most strains of mucoid P. aeruginosa are susceptible to colistin, whereas I. 
limosus are resistant (Kiska and Riddell, 2012).  
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 I. limosus has been cultivated on all Burkholderia cepacia selective media except 
Burkholderia cepacia selective agar (BCSA) due to incorporation of gentamicin.  The clinical 
microbiology laboratory at Virginia Commonwealth University Medical Center (VCUMC) uses 
BCSA in the primary battery of media for CF respiratory cultures.  Consequently, if I. limosus is 
present in patient samples, the BCSA will not support its growth.  Development and 
incorporation of media selecting for this organism is needed to determine the presence of I. 
limosus in CF patients at VCUMC (Coenye et al., 2002; Hayes et al., 2009). 
 Over the past 10 years, much attention has been devoted to developing and implementing 
molecular techniques, such as MLST, Sanger sequencing, and pyrosequencing to characterize the 
microbial epidemiology of CF airways. As a result, little effort has been spent on revisiting and 
revising CF microbiology protocols and the classic list of CF pathogens.  Although molecular 
methods provide a vast amount of information regarding the CF lung microbiome, it is not 
currently feasible to adopt in the clinical setting due to cost and labor intensiveness.  With the 
growing body of literature reporting on the presence of emerging pathogens in CF and their 
potential role in disease progression, culture protocols must be reviewed and optimized in order 
to provide clinicians with the data needed to manage and treat CF patients (Miller & Gilligan, 
2003; Armougom et al., 2009).  
Purpose and Specific Aims 
 The purpose of this study was to expand data relevant to the use of microbiology cultures 
for the management and treatment of CF patients at VCUMC. Three specific aims guided this 
study.  Refer to Table 1 for an overview. 
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Table 1. Overview of Specific Aims 
 
Specific Aims Steps to Accomplish Aims 
SA1:  Develop culture-dependent screening 
protocols to detect emerging pathogens in the 
CF population at VCUMC. 
 
Incorporate previously developed agar to 
select for SAG and anaerobes and develop 
agar to select for colistin-resistant NF GNRs 
in CF respiratory cultures. 
 
SA2:  Determine the prevalence of emerging 
CF pathogens in the patient population at 
VCUMC. 
 
Calculate the prevalence of targeted emerging 
pathogens recovered in culture from CF 
patients at VCUMC. 
SA3:  Prospectively evaluate current culture 
techniques in conjunction with newly 
developed and implemented protocols. 
 
Compare culture results from the routine and 
research protocols and document 
discrepancies. 
 
Specific aim 1.  Develop culture-dependent screening protocols to detect emerging 
pathogens in the CF population at VCUMC. Members of the SAG, anaerobes, and colistin-
resistant NF GNR, which have been recognized as emerging CF pathogens that may play a 
significant role in the onset of PE, were targeted.  McKay agar, a semi-selective solid medium 
for SAG was added to the routine battery of media.  Anaerobic media and anaerobic incubation 
conditions were utilized to detect this select group of organisms.  Development and 
implementation of an agar-based medium supplemented with colistin sulfate was used to select 
for colistin-resistant NF GNRs.  Culture conditions were optimized in order to detect the 
presence of targeted or emerging pathogens in the CF population at VCUMC. 
Specific aim 2. Determine the prevalence of emerging CF pathogens in the patient 
population at VCUMC. The routine CF culture protocol selects for and cultivates the classic CF 
pathogens known to play a role in CF lung disease.  Molecular profiling studies have revealed 
the growing list of emerging pathogens thought to play a role in lung function decline.  The first 
step needed to investigate the potential role of emerging CF pathogens in a population is to 
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determine the prevalence.  Therefore, prevalences of SAG, anaerobes, and colistin-resistant NF 
GNR were calculated.   
Specific aim 3. Prospectively evaluate current culture techniques in conjunction with 
newly developed and implemented protocols. This aim was accomplished by comparing culture 
results from both the routine and research microbiology culture protocols.  Any organisms that 
were cultivated and identified in the research protocol only were recorded.  Any discrepant 
results between the routine and research protocols were evaluated.  
Significance of Study 
 CF affects approximately 70,000 individuals worldwide (CF Foundation, www.cff.org).  
Routine surveillance of CF pathogens at individual CF centers are used to track and trend the 
incidence and prevalence of specific organisms and remains the method of choice to effectively 
manage CF patients.  There has been an increased interest in developing molecular methods to 
uncover members of the CF lung microbiome.  These molecular profiling studies have been very 
useful in revealing the growing list of pathogens that may play a role in CF lung function 
decline; however, CF culture protocols have not been modified to detect these organisms.  
Traditional cultures succeed in recovering only the same well-characterized species and provide 
an incomplete picture of bacteria in the airway that could either directly or indirectly contribute 
to lung function decline in this population. Therefore, the current CF protocol for culturing, 
isolating, and identifying CF pathogens needs to be reviewed, revised, and updated to include 
emerging pathogens strongly associated with worsening clinical status. The presence of 
emerging pathogens and their role in CF lung disease cannot be ignored.  If present in clinical 
specimens, emerging pathogens must be reported in order for clinicians to make informed 
decisions and provide optimal care when managing and treating CF patients. 
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Chapter 2:  Literature Review 
 
Introduction 
 The following chapter will present background information relevant to CF.  First, CF will 
be described in general terms to include the following: inheritance patterns, incidence, CFTR 
protein and function, CFTR mutations, carrier screening and detection, treatment and infection 
control, pulmonary exacerbations and classic CF pathogens.  Next, information related to the 
lung microbiome will be presented highlighting emerging pathogens, oral flora, SAG, anaerobes, 
and NF GNRs.  Finally, molecular profiling methods and culture-dependent methods used to 
isolate both classic and emerging CF pathogens will be summarized.   
Cystic Fibrosis 
 CF is an autosomal recessive disorder that affects approximately 30,000 children and 
adults in the United States (US) and over 70,000 individuals worldwide (CF Foundation, 
www.cff.org).  The incidence in the US for Caucasians, Hispanics, Asians, and African 
Americans is 1 in 2,500 to 3,500, 1 in 4,000 to 10,000, 1 in 100,000, and 1 in 15,000 to 20,000, 
respectively.  Approximately 1,000 new cases of CF are diagnosed each year with a median 
predicted survival of 41 years (CF Foundation, www.cff.org).   
 This chronic disease, affecting the lungs and digestive system, is caused by mutations in a 
single gene located on the long arm of chromosome 7 (7q.31.2) that encodes the cystic fibrosis 
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transmembrane conductance regulator (CFTR) protein.  More than 10 million Americans are 
symptomless carriers of the defective genes which make CF the most common life-shortening 
disorder in Caucasians (CF Foundation, www.cff.org).  Based on the autosomal recessive 
inheritance pattern, each time two carriers of a defective CF gene have a child, there is a 25% 
chance the child will have CF, a 50% chance the child will be a symptomless carrier of a 
defective CF gene, and a 25% chance the child will neither carry a defective CF gene nor have 
CF.   
In 2001, CF carrier screening was incorporated into routine obstetric practice.  Molecular 
methods, such as the Amplification Refractory Mutation System (ARMS), multiplex PCR, and 
Next-Generation Sequencing (NGS) are employed for prenatal or carrier screening.  It is 
estimated that as many as 1 in 29 Caucasians are carriers of a defective CF gene with 
approximately 1,800 mutations documented to date.  In 2004, the American College of Medical 
Genetics recommended that a standard 23 mutation panel be used for prenatal or carrier 
screening.  This pan-ethnic panel consists of mutations present in at least 0.1% of those 
diagnosed with classic CF.  The spectrum of mutations is heterogeneous among ethnic groups; 
therefore, the sensitivity of carrier screening is as follows:  94% in Ashkenazi Jews to 88% in 
non-Ashkenazi North American Caucasians, about 72% in Hispanic Americans, 64% in African 
Americans, and 49% in Asians (American Congress of Obstetricians and Gynecologists, 
www.acog.org).  
Newborn screening for CF began in March 2006, and by 2010 was conducted in all 50 
states as well as the District of Columbia.  CF screening methods employed in state laboratories 
may vary; however, increased immunoreactive trypsinogen (IRT) levels in blood suggest CF and 
warrant additional testing in the newborn.  In some states, such as Virginia (VA), screens with 
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increased IRT levels reflex to DNA testing.  If CF gene mutation(s) are detected, confirmatory 
testing is performed.  The sweat chloride test is considered the standard diagnostic test with a 
result greater than or equal to 60 mmol/L confirming the disease.  Once definitively diagnosed, 
the CF genotype is determined by molecular methods. Most children are diagnosed by the age of 
two and a small number of CF patients with a milder form of the disease are not diagnosed until 
approximately 18 years of age.  Symptoms in newborns include delayed growth, failure to gain 
weight during childhood, absence of bowel movement in the first 24-48 hours of life, and salty 
tasting skin. (CF Foundation, www.cff.org).   
 The CF gene spans approximately 230 kb and is composed of 27 exons.  This gene is 
transcribed into a 6.5 kb messenger RNA (mRNA) that encodes a 1,480 amino acid (a.a.) 
protein.  More than 1,800 mutations of the gene have been identified to date; however, only 23 
mutations have been identified with a frequency of at least 0.1% of known alleles (Salvatore et 
al., 2011; Gibson et al., 2003; American Congress of Obstetrics and Gynecologists, 
www.acog.org).  The 1,800 mutations can be classified as CF causing mutations, mutations of 
unknown significance, mutations of varying clinical consequence, and non-CF causing mutations 
(CF Foundation, www.cff.org).  Delta F508 accounts for 70% of CF alleles in the Caucasian 
population.  This mutation is characterized by a three base pair deletion that codes for 
phenylalanine at position 508 of the CFTR protein (Gibson et al, 2003).   
The CFTR protein regulates the transepithelial ion flow of airway surface liquid (ASL).  
Mutations in the CFTR protein affect sodium and chloride ion transport, disrupting the ionic 
composition and volume of ASL.  Under normal circumstances, ASL is thin in consistency 
allowing clearance of inhaled microorganisms via ciliary action.  When CFTR mutations are 
present, ASL increases in viscosity which clogs the airways. This alteration impedes the 
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clearance of microorganisms; and as a result, mucosal surfaces are heavily colonized by 
microbes that contribute to progressive lung function decline over the lifetime of the patient.  
The neutrophilic inflammatory response is chronically activated in the presence of persistent 
microbes which ultimately lead to pulmonary failure and death in 95% of patients (Kiska & 
Riddell, 2012; LiPuma, 2010; Lynch & Bruce, 2013; Tunney et al., 2008). 
Treatment and infection control.  CFTR is expressed on epithelial cells found in the 
airway, paranasal sinuses, pancreas, gut, biliary tree, vas deferens, and sweat ducts. This protein 
is responsible for regulating the flow of salt and fluids in and out of cells.  Mutations in the gene 
that codes for the CFTR protein cause CF, which is truly a multisystem disease.  Pulmonary 
manifestations include sinusitis and persistent lung infections, characterized by chronic cough 
and sputum production, chronic wheezing, bronchiecstasis, and atelectasis.  In addition, 
pancreatic insufficiency and CF-related diabetes is also seen in this population (Spoonhower and 
Davis, 2016; Flume, 2009). Over the years, improved clinical outcomes are attributed to more 
effective formulations of pancreatic enzymes, mucolytic agents, airway clearance techniques, 
and antibiotic treatment regimens.  Despite the many advances, greater than 90% of CF mortality 
and morbidity are due to suppurative lung disease (Bell & Robinson, 2007).  Various treatment 
strategies exist to treat and manage this multisystem disorder.  For example, mucolytic agents, 
hypotonic saline, physiotherapy, and antibiotics are chronically prescribed to prevent PEs.  
Pancreatic enzymes and nutritional supplementation are used to provide and maintain nutritional 
support.  Periods of acute PE often involve hospitalization where additional antibiotics are 
administered intravenously. 
 Infection control among the CF population is imperative.  Pathogens, such as members of 
the BCC, are referred to as epidemic strains; that is, they may be acquired from another CF 
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patient or from contaminated environments.  This may occur through direct or indirect contact 
with infected respiratory secretions.  Infection control guidelines are issued by the American CF 
Foundation (CFF).  Recommendations include obtaining quarterly surveillance cultures, 
discouraging socialization among hospitalized CF patients, educating patients and families about 
hand hygiene and cleaning, and disinfecting nebulizers (Garber et al., 2008).  In addition, it is 
also recommended that CF patients wear hospital masks in healthcare settings, maintain a six 
foot separation from other CF patients, and limit the time spent in waiting areas (Saimanet al., 
2013). 
Pulmonary exacerbations. PEs are the leading cause of morbidity in CF patients.  Overt 
immunological responses in patients during periods of PE lead to irreversible lung damage 
(Sibley & Surette, 2011).  Clinical features of PE include the following:  increased cough, 
increased sputum production, shortness of breath, chest pain, loss of appetite, weight loss, and 
lung function decline.  Recurrent episodes of PE in CF patients are associated with long term 
decline in lung function and shortened survival (Zemanick et al., 2013).  Due to the chronic 
nature of this disease, PEs are difficult to treat.  The goal is not to clear the pulmonary infection 
but rather restore the patient back to baseline lung function.  Currently, there are no clinical or 
microbiological predictors of PE.  However, recent research has revealed the importance of 
changes in the dynamics of the microbial community in the lungs, such as microbial density and 
diversity, in relation to acute PEs (Jones, 2011; Sibley and Surette, 2011; Waite et al., 2012). 
 Microorganisms contributing to PEs vary in CF cohorts, and their specific role in the 
disease process remains unclear.  Microorganisms may directly produce virulence factors or 
upregulate virulence factors by interacting with other members of the microbial community in 
the lung which could lead to PE.  Antimicrobial therapy is usually guided by the presence of 
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classic CF pathogens grown in respiratory culture; however, their activity is broad and often 
effective against many other organisms.  Since the microbiome of the lung is so diverse, it is 
difficult to determine if antibiotics are targeting an unknown or emerging pathogen inadvertently 
which could possibly play a significant role in PE (Sibley & Surette, 2011).  Approximately 25% 
of patients fail to fully respond to culture-guided treatment of PE; therefore, investigating the 
presence and role of other possible contributors in the lung microbiome could have an effect on 
predicting and treating PE, as well as improving patient outcomes in this population (Zemanick 
et al., 2013). 
Classic CF pathogens.  Based on the natural history of CF, classic pathogens 
contributing to morbidity and mortality have been identified.  Early on, CF patients are colonized 
by S. aureus and H. influenzae.  This is followed by acquisition of P. aeruginosa, which over 
time, undergo phenotypic changes in the CF lung causing them to become mucoid, multi-drug 
resistant, and difficult to treat (Spoonhower and Davis, 2016; Waters, 2012).  In addition, other 
NF GNRs such as Stenotrophomonas maltophilia and Achromobacter xylosoxidans are 
frequently isolated.  Patients with more advanced disease are often infected with members of the 
BCC which is associated with a progressive decline in lung function (Mahenthiralingam, 2014; 
Parkins, Sibley, Surette & Rabin, 2008).  Organisms thought to play a secondary role in CF lung 
disease include respiratory viruses and fungi, such as Aspergillus fumigatus (Miller and Gilligan, 
2003).  Microbiological and molecular laboratory methods have described CF lower airways as 
polymicrobial; therefore, the list of classic pathogens and their role in CF should be revisited and 
possibly expanded to improve management and treatment of patients (Mahenthiralingam, 2014; 
Sibley et al., 2008). 
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Lung Microbiome 
 Molecular methods have demonstrated the dynamic community of microorganisms 
within the CF lung.  Many have not been grown in culture using standard CF protocols.  
Research suggests that microbiome composition and perturbations in these communities may 
impact pulmonary status.  Understanding the impact of this polymicrobial community on airway 
health is essential to improve patient care (Lynch & Bruce, 2013; Armougom et al., 2009). 
 Molecular methods, such as MLST, Sanger sequencing, and pyrosequencing, are based 
upon analysis of the genetic content of bacteria.  These techniques are more reproducible than 
phenotypic methods and provide greater discriminatory power when differentiating between 
epidemic and non-epidemic strains.  MLST is a popular method for bacterial genotyping.  DNA 
sequence variations in genes known to be present in all strains of a given species are measured 
and characterized by unique allelic profiles (Saiman et al., 2013). Pyrosequencing, a next 
generation sequencing method, detects pyrophosphate release on nucleotide incorporation, rather 
than dideoxynucleotides used in Sanger sequencing.  A complimentary strand of single stranded 
DNA is synthesized enzymatically hence the associated name, “sequencing by synthesis”.  
Thousands of 100 base pair sequences are generated without the need for cloning.  Theoretically, 
the number of sequences is proportional to the number of genomic copies present in the sample. 
Therefore, pyrosequencing evaluates the relative amounts of different species present.  The 
molecular methods described above are examples of massive sequencing techniques frequently 
employed by researchers conducting molecular profiling studies (Armougom et al., 2009). 
 The CF lungs are colonized by a diverse and dynamic community of bacteria, viruses, 
and fungi.  On average, the lungs of CF patients harbor 22 metabolically active microbial 
species.  These include the classic CF pathogens in addition to other species, such as members of 
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the oropharyngeal flora (OF) that have not been previously identified as significant in this 
population (Parkins et al., 2008; Olson et al., 2010).  The role and interspecies interactions of this 
complex community on patient outcomes remains poorly understood (Filkins et al., 2012).  
Rabin and Surette (2012) demonstrated through animal coinfection models that organisms in the 
CF lung considered to be nonpathogenic were capable of acting synergistically with the classic 
pathogen, P. aeruginosa, to dramatically increase disease.  The dynamic microbiome of the CF 
lung and bacterial community interactions could lead to enhanced pathogenesis and, therefore, 
must be considered to effectively guide and optimize the treatment strategies of CF pulmonary 
infections (Sherrard et al., 2013; Sibley et al., 2008; Sibley et al., 2010).  
Emerging Pathogens 
 Less prevalent or emerging organisms isolated from CF respiratory cultures could 
potentially affect microbial community dynamics in the lungs.  However, the role of these 
emerging pathogens in CF disease progression is unknown (Kiska & Riddell, 2012).  Typically, 
emerging pathogens are organisms not considered pathogens under normal circumstances.  
However, their ability to alter pathogenesis of the community through interspecies interaction 
may make them relevant.  For example, OF could serve as a reservoir of unrecognized pathogens 
in CF.  When these organisms travel to the lower airways, they may have the ability to cause 
disease within a polymicrobial context.  It has been determined that treatment of PE does not 
frequently impact pathogen load.  In many cases, the microbiology culture results remain 
unchanged before, during, and after treatment.  Research suggests that detecting the presence and 
investigating the role of emerging pathogens in CF patients may correlate with periods of clinical 
stability and PE (Sibley & Surette, 2011). 
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 The presence of emerging pathogens in the CF population is due to many factors.  
Frequent surveillance of CF patients is associated with an increased incidence and prevalence of 
specific organisms such as Ralstonia, Pandoraea, and other NF GNRs (Saiman et al., 2013).  
The predicted survival rate for CF patients in the US increased from 28 years in 1990 to 
approximately 40 years today.  This provides a greater opportunity for previously considered 
nonpathogenic microbial species to colonize and infect the lower airways.  CF patients are 
commonly prescribed chronic suppressive antimicrobial therapy to manage their disease.  In 
addition, when classic CF pathogens are initially isolated in culture, eradication is attempted with 
aggressive therapy.  Exposure to multiple antibiotics in high doses over long periods of time 
places greater selective pressure on organisms which could contribute to infection.  Further, 
within the dynamic microbiome of the lung, microbial species may acquire genes encoding 
virulence factors.  This could result in an increased capacity to cause infection (LiPuma, 2010). 
 The use of selective media in the clinical microbiology laboratory has revealed emerging 
pathogens with potential impact on the lung’s microbial community.  An example is BCSA.  
Phenotypically similar organisms, such as Ralstonia and Pandoraea are able to grow on this 
media as well.  Resemblance to B. cepacia, a classic pathogen associated with lung function 
decline and poor outcomes, brings into question their role in the CF lung.  As development and 
use of improved laboratory methods continues, emerging pathogens will be isolated with 
increased frequency (Miller & Gilligan, 2003).   
 The classic CF pathogens have been documented to play a role in progression of lung 
disease.  The increased presence of emerging pathogens in this population warrants an 
investigation of their prevalence in the CF community as well as their impact on lung function in 
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this unique ecological niche.  It is conceivable that they, too, belong on the classic CF pathogen 
list (Vrankrijker, Wolfs & van der Ent, 2010.) 
Oral flora.  Based on molecular profiling studies, the CF airways are colonized by many 
polymicrobial communities consisting of organisms referred to as normal OF (Field et al., 2010).  
The oral cavity is colonized with hundreds of species of bacteria such as Streptococcus, 
Veillonella, Prevotella and Gemella which have all been identified as community members of 
the lung microbiome.  Historically, when members of the OF were found in sputum cultures, 
their presence was attributed to specimens contaminated by bacteria in the oral cavity.  In fact, 
the classic list of CF pathogens do not contain any OF flora, and specific culture conditions are 
not utilized to target this group of organisms.  Research has confirmed the true presence of OF 
flora in the lower airways of CF patients rather than sample contamination as it passes through 
the oral cavity.  It has also been well documented that members of the OF flora act as synergens 
in the CF lung by enhancing the virulence of P. aeruginosa (Field et al., 2010; Sibley et al., 
2008; Waite et al., 2012). 
Streptococcus anginosus group.  The presence of SAG in the CF lung and their role in 
acute PE has been highlighted.  There are three members of the SAG:  Streptococcus 
constellatus, Streptococcus intermedius, and Streptococcus anginosus.  SAG colonize the 
oropharynx, gastrointestinal (GI) tract, and vagina in approximately 15-40% of the general 
population (Parkins et al., 2008; Sibley et al., 2010).  Members of this group have great 
pathogenic potential and are responsible for a wide variety of infections including brain and liver 
abscesses, empyema, as well as other purulent infections throughout the body.  In fact, when 
specifically sought, SAG can be identified in up to 25% of culture-negative pneumonia samples.  
Antibiotic therapy for SAG infections normally includes pencillin G, ceftriaxone, cefotaxime, 
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imipenem, and meropenem.  However, antimicrobial susceptibility patterns of CF SAG isolates 
may differ due to chronic antibiotic exposure (Parkins et al., 2010).  
 SAG are phenotypically diverse within species making isolation and identification a 
difficult task for the clinical laboratory.  Often times, they are indistinguishable from other 
streptococci that have little or no known pathogenic potential.  SAG typically exhibit slow 
growth rates, a distinctive caramel smell, and the inability to ferment sorbitol. Various patterns 
of hemolysis including alpha, beta, and gamma are observed in culture.  Lancefield grouping is 
inconsistent among this group: A, C, F, G, and non-typeable results have been obtained (Olson et 
al., 2010). 
  The presence of SAG is often underrepresented in culture due to the battery of media 
and incubation conditions used to target only classic CF pathogens even when it is the 
numerically dominant pathogen (Grinwis et al., 2010).  In addition, these organisms could have 
fastidious growth requirements that are not adequately provided in standard culture media 
(Parkins et al., 2008).  As a result, the clinical significance of SAG in CF lung disease has been 
overlooked (Sibley et al., 2008).  Until recently, SAG have not been considered to play a role in 
CF lung disease.  Due to their strong correlation with clinical status, propensity to cause 
pyogenic infections, and antibiotic resistance in this population, SAG is now being considered a 
CF pathogen (Sibley et al., 2008; Sibley and Surette, 2010). 
Grinwis et al. (2010) characterized 128 SAG isolates from the sputum of adults with CF.  
Forty-five SAG isolates from non-CF patients with invasive disease were used for comparison.  
The following tests were performed on both sets of isolates: Lancefield grouping, tests for 
hemolysis, tests for production of hyaluronidase, chondroitin sulfatase, DNase, proteases, 
hydrogen peroxide, and PCR detection of the intermedilysin gene.  Upon comparison of group 
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strains (CF vs. non-CF), S. intermedius isolates were similar while S. constellatus and S. 
anginosus yielded several biotypes.  Approximately 75% of S. constellatus CF isolates were 
beta- hemolytic Lancefield group C compared to 13.3% of invasive isolates from non-CF 
patients.  Another key difference between groups included hyaluronidase-positive S. anginosus 
strains found only in CF isolates, indicating increased virulence in this population.  Cluster 
analysis revealed both strain groups clustering together which suggests that CF isolates and 
invasive isolates are equally pathogenic (Grinwis et al., 2010).  These data supports the need to 
further investigate the role of SAG in CF lung disease. 
Due to the pathogenic potential of SAG and possible contribution to PE, Sibley et al. 
(2010) conducted a six-month surveillance study on a Canadian CF cohort using McKay agar.  
McKay agar is a semi-selective solid medium used to isolate SAG from nonsterile body sites, 
such as the CF airways.  A total of 108 patients were screened in the surveillance study.  From 
those, a total of 226 samples were collected (180 surveillance samples and 46 exacerbation 
samples).  During the six-month period, SAG was isolated from eight of the 108 specimens on at 
least three separate occasions at levels associated with chronic colonization.  SAG was common 
in this adult CF cohort with a specimen prevalence rate of greater than 40%.  Further, SAG in 
concentrations greater than 10
7
 cfu/mL was associated with a decline in clinical status.  This 
supports the idea that SAG play a role in the progression of CF lung disease (Sibley et al., 2010). 
Parkins et al. (2008) reported on six cases of SAG-related infection over four years in a 
Canadian adult CF cohort.  SAG was found in patients co-colonized with P. aeruginosa.  
Previous studies have shown that pathogenicity of SAG and other viridians streptococci are 
enhanced within a polymicrobial context supporting a microbial interaction between SAG and P. 
aeruginosa.  The presence of SAG in the lower airways colonized with P. aeruginosa may prove 
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to be a significant finding.  Therefore, detecting the presence of SAG in CF lower airways is 
warranted (Parkins et al., 2008). 
 Studies characterizing the microbial epidemiology of CF patients report SAG as the 
numerically dominant organism at the onset of PE (Grinwis et al., 2010; Sibley et al., 2010; 
Parkins et al., 2008; Sibley et al., 2008).  Established CF protocols do not specify this organism 
as a pathogen; therefore, specialized culture conditions are not employed to seek SAG.  In a 
study by Sibley et al. (2008), a sputum sample was collected from a patient experiencing an 
acute PE before the initiation of antibiotics.  Using McKay agar, culture revealed SAG as the 
numerically dominant organism.  Using the culture to guide therapy, IV ceftriaxone was selected 
for treatment.  Ceftriaxone has no anti-pseudomonal activity which is usually one of the main 
targets when selecting an antimicrobial regimen.  Remarkably, S. constellatus responded to the 
ceftriaxone which resolved the clinical symptoms of PE as well as restoring baseline lung 
function. Subsequent cultures (six days post treatment) did not grow S. constellatus.  Without the 
addition of McKay agar, S. constellatus would not have been detected.  The presence of SAG is 
not evident on routine CF media due to overgrowth of classic CF pathogens such as P. 
aeruginosa (Sibley et al., 2008).  During this study period, the same patient experienced another 
PE.  The identical culture picture was observed which prompted the previously described 
treatment strategy.  Again, targeting S. constellatus resolved symptoms (Sibley et al., 2008).   
The importance of SAG has also been recognized by Zhao et al. (2012) who reported that 
SAG were persistent and abundant in all patients included in their longitudinal study (nine years, 
n=6).  Based on these findings, acknowledging the role of SAG in PE as well as modifying 
culture conditions to detect this group in CF pulmonary samples is necessary to provide optimal 
patient care. 
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Anaerobes.  Recent attention has been directed toward anaerobes and their possible role 
in CF lung disease.  Steep oxygen gradients and regions of hypoxia in the CF lung make a 
hospitable environment for anaerobes.  Molecular analysis of CF airway samples has revealed 
obligate and facultative anaerobes in high quantities during periods of PE.  At this time, their 
specific role in this process is not defined (Zhao et al., 2013).  Sherrard et al. (2016) suggest that 
fluctuation in the abundance of anaerobes could possibly be used as a marker of clinical status. 
When specifically sought, anaerobes has also been isolated and identified in culture (Field et al., 
2010; LiPuma, 2010).  However, it is difficult to obtain a pure culture which could lead to 
underestimating the importance of anaerobes in CF lung disease. 
 Tunney et al. (2008) reported Prevotella, Veillonella, Propionibacterium, and 
Actinomyces in high quantities, defined as 10
4
 ≤ n ≤9 x 107 cfu/g of sputum, from 42 out of 66 
adult CF sputum samples.  Similar findings were described in the pediatric population.  
Interestingly, different species of anaerobes in much lower quantities (10
2
 to 10
5
 cfu/g of 
sputum) were detected in respiratory samples from healthy volunteers.  These data suggests high 
quantities of species specific anaerobes may be unique to CF patients and may play a role in lung 
disease. Colonization with P. aeruginosa significantly increased the likelihood that anaerobic 
bacteria would be detected in the patient samples (Tunney et al., 2008).  It is possible that 
mucoid strains of P. aeruginosa render the airways anaerobic, which promotes the growth of this 
specific group of organisms.   
 Virulence factors of anaerobes isolated in CF specimens include the following:  secretion 
of extracellular enzymes such as proteases and B-lactamases, capsule production, biofilm 
formation, neutrophil chemotaxis, and resistance to phagocytosis.  These factors could all 
contribute to periods of acute PE and lung damage.  The presence of anaerobes in CF sputum 
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samples in equal or greater quantities than classic pathogens such as P. aeruginosa should be 
considered when managing patients (Tunney et al., 2008). 
 Rabin and Surette (2012) observed a correlation between bacterial load in CF clinical 
specimens in which the anaerobe Gemella species was detected and bacteriologic response in 
patients suffering exacerbations.  This raises awareness and suspicion of Gemella’s role in CF 
lung disease.  A 10-year longitudinal study following six CF patients reaffirmed that anaerobes 
are common and abundant in the CF lung.  Veillonella species and Prevotella species were most 
frequently seen (Zhao et al., 2012). 
 Prevotella species are obligate anaerobic bacteria that have recently been detected in CF 
respiratory samples.  Normally, Prevotella are isolated as normal members of oral, intestinal, and 
urogenital flora.  Prevotella has been associated with a wide variety of infections ranging from 
periodontal disease and lower respiratory tract infections to bacteremia.  Field et al. (2012) 
reported that Prevotella was isolated from the airways of 80% of CF patients examined in greater 
or equal quantities than that of classic aerobic pathogens.  A mouse coinfection pneumonia 
model demonstrated the synergistic effect of Prevotella intermedia and S. constellatus on the 
severity of symptoms and mortality.  These findings support the theory of polymicrobial 
interactions enhancing virulence of emerging CF pathogens (Field et al., 2010).  
Mahenthiralingam (2014) cites Prevotella species as an emerging pathogen and novel CF 
microbiome player.  Prevotella species persist in the lungs of CF patients receiving chronic 
antimicrobial therapy; however, their association with CF lung disease is not understood. 
 Sherrard et al. (2016) propose several mechanisms in which anaerobes may contribute to 
lung disease.  Interspecies interactions among anaerobes and classic CF pathogens are 
hypothesized to enhance pathogenicity and colonizing ability of P. aeruginosa.  Anaerobic 
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bacteria such as P. melaninogenica, V. parvula, and F. nucelatum secrete various short chain 
fatty acids which can lead to neutrophil recruitment and activation, ultimately causing 
inflammation in the lung.     
 The exact role of anaerobes in CF lung disease is unknown.  Anaerobes isolated from CF 
patients exhibit more resistant antimicrobial susceptibility patterns when compared to healthy 
controls, which can complicate treatment regimens if not specifically targeted. (Sherrard et al., 
2016).  In addition, the presence of anaerobes in significant quantities may contribute to 
inflammation and CF lung infection; therefore, their presence in clinical specimens and possible 
role in disease progression should be considered when managing CF patients (Sherrard et al., 
2013). 
Glucose non-fermenting Gram-negative rods.  The isolation frequency of glucose NF 
GNRs other than P. aeruginosa and BCC is increasing in CF respiratory samples.  The majority 
of these bacteria are environmental, multi-drug resistant organisms that persist in the CF lung 
even after aggressive antibiotic therapy.  The emergence of these organisms in the CF lung is due 
to several factors.  The CF population is aging.  An increased life span creates an opportunity for 
emerging organisms to colonize the CF lung.  In addition, chronic suppressive therapy in this 
population could select for multi-drug resistant organisms able to persist in the lower airways 
(Bittar & Rolain, 2010; Kiska & Riddell, 2012). 
 The pathogenic role of NF GNRs in the CF lower airways is unclear.  Multi-drug 
resistance patterns, in addition to biofilm formation, are cause for concern because few effective 
antibiotics are available for treatment.  The emergence of this distinct group has caused problems 
for the clinical microbiology laboratory as well.  Commercial identification systems routinely 
employed in clinical laboratories are unable to correctly identify many of these emerging 
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organisms.  Due to similarities among NF GNR phenotypic characteristics, they are often 
misidentified as BCC.  Colonization with BCC is associated with advanced lung disease and has 
severe psychosocial consequences for the patient (Kiska & Riddell, 2012). 
 Kiska and Riddell (2012) made many recommendations in regard to the presence of NF 
GNR in CF samples.  First, any glucose NF GNR that grows on B. cepacia selective agar should 
be identified.  Since limitations with current commercial identification systems exist, these 
isolates should be sent to reference laboratories for full identification.  This is considered good 
laboratory practice for all clinical microbiology laboratories.  Secondly, great consideration and 
attention should be given to any NF GNR resistant to colistin.  Since colistin is usually reserved 
as the last line of defense for multi-drug resistant P. aeruginosa isolates, other NF GNRs 
exhibiting resistance to this particular antimicrobial is concerning and its presence warrants 
investigation.   
 The emergence of NF GNRs in the CF population has been highlighted in several case 
reports.  Inquilinus limosus, a nonsporulating NF GNR exhibits multi-drug resistant patterns and 
is associated with poor clinical outcomes.  Acquisition of I. limosus by a 20-year-old male with 
CF resulted in clinical, spirometric, and radiographic lung function decline.  This isolate had a 
mucoid phenotype displaying multi-drug resistant susceptibility patterns.  Forced expiratory 
volume (FEV1) six months before isolating I. limosus was 3.12 L.  Chronic colonization with 
this organism resulted in a decreased FEV1 (2.65 L).  This particular case supports the 
pathogenic potential of I. limosus in the CF population (Hayes et al., 2009). 
 Chiron et al. (2005) reported on five CF patients with I. limosus-positive respiratory 
cultures.  In four of the five patients, I. limosus was isolated from at least seven sputum 
specimens indicating chronic colonization.  Susceptibility testing indicated all isolates were 
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resistant to penicillins, cephalosporins, kanamycin, tobramycin, fosfomycin, colistin, 
doxycycline, and co-trimoxazole.  I. limosus was susceptible to imipenem and ciprofloxacin.  
Similar to previous reports, lung function decline was observed in one patient following 
acquisition of I. limosus despite treatment targeting this organism.  The clinical impact of this 
organism remains unknown; however, its pathogenic potential and association with lung function 
decline should be recognized (Chiron et al., 2005). 
 Pandoraea species have also been isolated from the sputum of CF patients.  Like many of 
the other emerging NF GNRs, their role in CF lung disease is unclear.  These isolates are 
problematic for several reasons.  In the clinical microbiology laboratory they are often 
misidentified as members of the BCC or Ralstonia species.  In addition, antimicrobial 
susceptibility in these species is generally limited to tetracycline, imipenem, and trimethoprim-
sulfamethoxazole.  Misidentification and multi-drug resistant susceptibility patterns have a direct 
impact on patient outcomes (Costello, 2010). 
Laboratory Identification Methods 
Molecular methods.  Over the past decade, molecular methods, such as MLST, Sanger 
sequencing, and, pyrosequencing, have been performed in research settings, and have revealed 
the dynamic and diverse microbial communities occupying the CF lung. Based on these data, 
there has been a renewed interest in organisms typically considered clinically insignificant in this 
population, such as anaerobes and other members of the OF.  Many of the organisms identified 
by molecular profiling studies are not grown in culture with standard media and incubation 
conditions, and/or are overgrown by those dominating the community.  Although molecular 
methods provide a wealth of information, they are not a component of routine CF care in the US.  
Clinically, the molecular methods listed above are only performed when epidemiologically 
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indicated, such as strain typing BCC, and other organisms such as P. aeruginosa and NTM 
(Saiman et al., 2013).  Organism growth in culture is essential to functionally characterize, 
isolate, and determine susceptibility patterns (Bittar & Rolain, 2010; Sibley et al., 2008; Zhao et 
al., 2012).  Therefore, this study used information gleaned from molecular profiling analyses to 
develop culture-dependent screening methods for emerging pathogens suspected to play a role in 
CF lung disease.  Again, once grown in culture, emerging pathogens can be functionally 
characterized. 
Microbiology culture. Antimicrobial treatment regimens and patient management are 
dependent on the isolation and identification of CF pathogens.  Classic pathogen identification 
protocols involve Gram stain, growth at different temperatures on various routine and selective 
media, and antibiotic susceptibility testing (Bittar & Rolain, 2010).  CF respiratory cultures are 
used to detect new pathogens, guide therapy, monitor the success of eradication strategies, and 
distinguish transient from persistent colonization (Saiman et al., 2013).   
 CF respiratory cultures remain the most accurate method available to obtain data on 
classic pathogens known to play a role in disease progression (Rabin & Surette, 2012).  In fact, 
active surveillance using molecular methods is not a component of routine CF care in the US 
(Saiman et al., 2013).    The routine battery of media used for CF specimens consist of BA, 
CHOC, CNA, MAC, MS, and BCSA.  However, there are disadvantages to these media that 
pose challenges to the laboratorian. Mucoid strains of P. aeruginosa often invade the agar, and 
obscure the growth of Gram-positive organisms and slower growing Gram-negative organisms.  
In addition, this organism can produce substances that inhibit the growth of other bacteria (Bittar 
& Rolain, 2010; Gibson, Burn & Ramsey, 2003).  Table 2 describes the purpose of each media 
type included in routine CF culture protocols. 
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Table 2. Purpose of Routine CF Culture Media 
Media Type Purpose 
Blood Agar (BA) Isolation and detection of hemolytic activity of 
streptococci and other fastidious microorganisms.   
Chocolate Agar (CHOC) Isolation and cultivation of a variety of fastidious 
microorganisms.   
Columbia Nalidixic Acid (CNA) Selective isolation, cultivation, and differentiation of 
Gram-positive cocci from clinical specimens. 
MacConkey Agar (MAC) Selective isolation and differentiation of coliforms and 
enteric pathogens based on the ability to ferment 
lactose. 
Mannitol Salt (MS) Selective isolation, cultivation, and enumeration of 
staphylococci from clinical specimens.   
Burkholderia cepacia Selective Agar 
(BCSA) 
Selective isolation of B. cepacia from respiratory 
secretions of patients with CF. 
 
Adapted from Manual of Clinical Microbiology, 2011. 
 
 Selective media, such as BCSA, is used to detect members of the BCC.  Phenotypically 
similar organisms, however, have the ability to grow on such media which could lead to 
misidentification.  For example, other glucose NF GNRs such as Ralstonia, Pandoraea, 
Inquilinus, and Herbaspirillium have the ability to grow on selective Burkholderia agar (Kiska & 
Riddell, 2012; Bittar & Rolain, 2010).  Although microbiology culture underestimates the 
diversity of organisms in the CF airway, it is routinely used in the majority of clinical 
laboratories to monitor and guide treatment of patients.   
Over the last decade, there has been an increased interest in developing molecular 
methods to uncover members of the CF lung microbiome.  As a result, little or no effort has been 
placed on revisiting and revising traditional microbiologic practices for CF.  This is problematic 
for several reasons.  It is not currently feasible for clinical microbiology laboratories to adopt 
expensive molecular methods for routine surveillance cultures of CF patients.  Molecular 
profiling studies have been very useful in revealing a growing list of emerging potential 
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pathogens that may play a significant role in CF lung function decline.  However, routine CF 
culture protocols have not yet been modified to detect these organisms.  In fact, laboratories 
often fail to detect a bacteriologic response of isolated principal pathogens to antibiotic treatment 
suggesting the presence of additional bacteria responsible for clinical symptoms.  Molecular 
profiling studies have indicated that if particular organisms are sought, selective media and 
conditions can be optimized to recover specific targets.  Review of the current CF culture 
protocol is warranted (Sibley et al., 2008; Sibley & Surrette, 2011).   
Culture results obtained utilizing current microbiology protocols do not accurately reflect 
all organisms in the CF lung.  Emerging pathogens, and even numerically dominant organisms, 
can be overlooked due to the battery of media employed and culture incubation conditions.  Due 
to cost and labor intensiveness, molecular methods such as MLST and pyrosequencing are not 
adopted by routine clinical laboratories.  Therefore, it is desirable to closely evaluate traditional 
CF culture protocols and their ability to isolate emerging pathogens thought to play a role in CF 
disease progression as well as all classic pathogens.  
Conclusion 
Approximately 30,000 people in the US are diagnosed with CF and it is estimated that 
one in every 31 Americans are symptomless carriers of the defective CF gene.  In the last 
decade, more effective treatment strategies have improved patient outcomes.  Based on the 2012 
CF Foundation National Patient Registry Annual Data Report, the median predicted survival of 
an individual diagnosed with CF is approximately 40 years of age.  Despite these advancements, 
95% of deaths are due to respiratory failure.  Chronic bacterial lung infections eventually lead to 
lung function decline.  Culture-dependent methods are currently used in the US to monitor CF 
patients during both periods of clinical stability and PE. Data from molecular profiling studies 
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reveal that there is a diverse microbial community in the CF lung that is not being captured using 
the routine battery of media for culture.  The classic CF pathogens are routinely cultivated using 
current microbiology protocols; however, the presence of emerging pathogens thought to play a 
direct or indirect role in CF lung function decline are often overlooked or missed due to 
limitations of media and incubation conditions.  In order to determine the role of emerging 
pathogens in this population, they need to be directly sought in culture.   This study proposed to 
expand microbiology culture strategies for management and treatment of CF patients at VCUHS.   
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Chapter 3:  Materials and Methods 
 
Introduction 
 Current CF culture protocols only select for classic CF pathogens known to play a role in 
lung disease.  There is a growing list of emerging pathogens associated with PE and lung 
function decline.  Culture-dependent screening protocols were utilized to select for emerging 
pathogens in CF respiratory specimens in order to determine their prevalence in the population at 
VCUMC.  This chapter covers the research design of the study which includes population and 
sample collection, specimen transport, specimen processing, as well as methods used to 
accomplish the goal of expand the use of microbiology cultures strategies to improve 
management and treatment of CF patients at VCUMC.  The following specific aims contributed 
to accomplishing this goal: 
Specific aim 1.  Develop culture-dependent screening protocols to detect emerging 
pathogens in the CF population at VCUMC. 
Specific aim 2.  Determine the prevalence of emerging CF pathogens in the patient 
population at VCUMC. 
Specific aim 3.  Prospectively evaluate current culture techniques in conjunction with 
newly developed or proposed protocol. 
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Research Design 
Population and sample. The population for this study consisted of adult and pediatric 
CF patients treated at VCUMC.  A convenience sample was used, which consisted of all residual 
respiratory cultures collected from CF patients during routine clinic visits or hospitalizations that 
were submitted to the clinical microbiology laboratory at VCUMC for diagnostic purposes from 
July to September 2016.  Inclusion criteria consisted of all specimen types collected from CF 
patients including Eswabs and sputum.  Respiratory samples were excluded if the quantity was 
insufficient to inoculate the proposed study media.  
Typically, CF patients are monitored on a quarterly basis during periods of clinical 
stability; therefore, four encounters are estimated per patient per year.  Signs of PE require 
additional encounters which often times result in hospitalization.  A respiratory sample is 
collected at each visit and hospitalization to guide treatment.  There are two separate CF clinics 
operated by VCUMC.  One clinic serves the pediatric CF population, and the other serves the 
adult CF population.  The pediatric and adult populations are distinguished by their 18
th
 birthday. 
  During 2011-2012, 142 patients were seen in the CF clinic.  This number may reflect 
multiple encounters for some patients but not all due to non-compliance with recommended 
follow-up visits.  Based on these numbers, it was estimated that between 50 and 70 patients 
would be seen at either the adult or pediatric CF clinics at VCUMC for surveillance or be 
hospitalized for PE over the study time frame with at least one respiratory sample, in the form of 
Eswab or sputum, collected.  The rationale for sample size was determined based on collecting at 
least one data point (respiratory culture), either from routine surveillance or episodes of PE, from 
approximately half of CF patients seen at VCUMC. The study time frame began upon IRB 
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approval (June 2016) and ended when 75 CF respiratory samples, were prospectively evaluated 
(September 2016).  
Recruitment and IRB. This study presented no greater than minimal risk to the sample 
population, as residual CF patient respiratory samples ordered for diagnostic purposes were used.  
To protect patient confidentiality, coding was used when labeling the study media, recording 
data, and reporting results.  In addition, the research took place in the clinical microbiology 
laboratory at VCUMC, located in the Clinical Support Center, 5th floor which is not a patient 
care facility. 
 A waiver of authorization was requested and granted for this study.  The second aim was 
to determine the prevalence (see methods for Specific Aim 2) of emerging CF pathogens in the 
patient population at VCUMC. In order for the true prevalence of emerging pathogens in the CF 
population at VCUMC to be determined over the study period, all residual CF respiratory 
samples were included in the study. If only a portion of these samples were included, based on 
patient consent, the sample would have been biased; therefore, true prevalence could not have 
been determined. As a result, the waiver of authorization was needed to fully and accurately 
accomplish the second aim.  IRB approval for this expedited study (HM20001275), which 
included a waiver of authorization to allow all CF respiratory samples collected during the study 
time frame to be included, was granted in June 2016. 
Specimen collection and transport. Respiratory samples in the form of expectorated 
sputum or Eswabs were collected from each CF patient by clinicians or nurses according to 
standard operating procedure during all routine clinic visits, and termed “surveillance cultures”.  
In addition, respiratory samples, which included Eswabs or sputum, were also collected by health 
care providers from patients during periods of hospitalization due to PE.   
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If a patient was able to expectorate, a sputum sample was obtained in a sterile collection 
container.  For patients unable to produce sputum, an ESwab was used for collection.  Copan 
ESwab is a liquid-based multipurpose collection and transport system that maintains viability of 
aerobic, anaerobic, and fastidious bacteria.  The health care provider removes the flocked swab 
from the package.  Immediately after swabbing the tonsillar pillars or cough secretions of the 
patient, the swab is placed in the sterile transport system containing one milliliter of modified 
liquid Amies medium.  This allows the entire sample to elute into the medium providing up to 10 
identical 100 microliter aliquots of liquid sample suspension.  Specimen collection using Eswabs 
or expectorated sputum constituted no more than minimal risk; any possible adverse effects (e.g., 
gagging, discomfort) were overshadowed by the potential benefit to the CF patients. 
All respiratory specimens, whether in the form of sputum or ESwabs, were properly 
labeled in the CF clinic or hospital floor by health care providers collecting the sample and sent 
to the clinical microbiology laboratory at VCUMC for culture.   Figure 1 depicts routing of 
patient specimens for routine CF culture and the research protocol.  Refer to Appendix A for the 
routine CF culture protocol utilized in the clinical microbiology laboratory at VCUMC. 
Specimen processing. Upon receipt in the clinical microbiology laboratory, respiratory 
specimens were accessioned by laboratory personnel which prompted culture-specific labels to 
print. CF cultures generated six labels with the following information:  patient name, medical 
record number, accession number, collection and receipt date and time, culture type, and 
respective culture media (BA, CNA, CHOC, MAC, BCSA, MS).  The sputum, Eswab, or BAL 
submitted for culture was processed according to standard operating procedure for diagnostic 
testing in the clinical microbiology laboratory upon receipt. CF sputum samples were 
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Figure 1.  Routing of CF Respiratory Specimens for Routine and Research Culture Protocols 
 
 
treated with Copan SLsolution.  This solution contains Dithiotreitol (DTT), a mucolytic agent, 
which emulsified the sputum and mucus.  The resulting homogenous suspension was vortexed 
and used to inoculate the battery of culture media.  ESwabs collected for CF respiratory cultures 
were vortexed for five seconds, and the liquid-based medium was used to inoculate agar plates 
for culture.  All media were then placed in the appropriate incubation conditions. Residual 
samples were immediately stored in refrigerated temperatures for seven days.   
 All residual CF respiratory samples were retrieved for the study protocol, which was 
accomplished by requesting a pending log queried through the laboratory information system 
(LIS), Cerner.  Pending logs were generated each day during the study period to determine if CF 
respiratory samples were submitted to the clinical microbiology laboratory for culture.  If 
CF Respiratory Specimens 
 
Sputum or ESwabs 
 
 
 
Routine CF Culture Analysis 
 
Blood agar, CNA, Chocolate agar, MacConkey agar, BCSA, MS 
 
 
 
 
Residual CF Sample Used for Research Protocol 
 
Blood agar, TSA w/ colistin and vancomycin, MAC w/ colistin (35°C, ambient air) 
McKay Agar (SAG), Brucella, PEA, LKV/BBE (35°C, anaerobic conditions) 
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cultures were submitted, residual samples were retrieved from their designated storage space in 
the refrigerator.  These samples were coded and inoculated to the study media which included 
one plate each of the following media: BA, McKay agar, MAC, MAC with colistin, and TSA 
with colistin and vancomycin. All study media were placed in the appropriate incubation 
conditions. 
 For each CF respiratory specimen included in the study, the following information was 
recorded:  patient name, medical record number, date of birth, age, sex, accession number, 
location, and diagnosis.  To protect patient confidentiality, a three-part study number was 
assigned to each specimen and all study media were labeled only with study numbers. The first 
represented the patient, the second the date, and the third the sample number. The first number 
was unique to each patient and not repeated for respiratory specimens submitted by different CF 
patients. This ensured that the desired number of respiratory samples from individual CF patients 
were included in the study. For example, if there were four residual samples from four different 
patients on a given day, they were coded as follows: 1.5.9.16.01, 2.5.9.16.01, 3.5.9.16.01, and 
4.5.9.16.01. If a residual sample from the same patient was repeated throughout the study period, 
the first digit of the culture number remained the same, however, the date and sample number 
changed (Example: 1.6.1.16.02).    
Specific Aim 1 
Based on their potential pathogenicity and association with PEs and lung function 
decline, the following emerging pathogens were sought in culture:  SAG, anaerobes, and colistin-
resistant NF GNRs.  A protocol to identify these targeted emerging pathogens in CF respiratory 
cultures was developed by evaluating the study media for over a seven-day incubation period and 
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determining a work-flow for presumptive and definitive identification when suspicious colonies 
were observed.  
Culture identification of SAG.  McKay agar, which selects for members of the SAG, 
was used to culture this group of emerging pathogens in the respiratory samples of CF patients at 
VCUMC. Routine CF microbiology protocols are inadequate to detect SAG in patient 
specimens.  Incorporation of a semi-selective media to separate and isolate these potential 
pathogens in this patient population is warranted (Parkins et al., 2008).  Sibley et al. (2008) 
developed a semi-selective solid medium, McKay agar, for detecting SAG from non-sterile body 
sites such as CF airways.  The following are needed to make 1 liter of  McKay agar:  13.3g 
nutrient broth, 5g glucose, 10g yeast extract, 5g tryptone, 2g K2HPO4, 40 ml salt solution, 1 mL 
Tween 80, 1 mg crystal violet, 60 mg bromcresol purple, 10 ug vitamin K, 0.005 g haemin, and 
15 g Bacto agar.  The pH is adjusted to 7.2 before autoclaving.  The sterilized medium is then 
supplemented with 20 mL L-arginine (2.5% w/v) and filtered antibiotic stock solutions of:  
sulfadiazine, colistin sulfate and oxolinic acid to final concentrations of 500, 10, and 5 ug/mL, 
respectively.  Colistin and oxolinic acid are added to inhibit the growth of two classic CF 
pathogens:  S. aureus and P. aeruginosa.  Sulfadiazine is incorporated to select for SAG against 
other viridians streptococci. SAG isolates produce an acid environment on McKay agar which is 
detected by the colorimetric pH indicator, bromcresol purple.  The above formula was provided 
to Teknova Inc., a manufacturing company that prepared the custom McKay agar for use in this 
study. 
Quality control.  Quality control testing was conducted weekly throughout the study 
period to verify that McKay agar selectively cultivated SAG.  This was accomplished using 0.5 
McFarland standard suspensions of the following American Type Culture Collection (ATCC) 
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strains: S. anginosus (ATCC 33397), S. intermedius (ATCC 27335), S. constellatus (ATCC 
27823), and S. aureus (ATCC 29213).  Each strain was inoculated to a different McKay agar 
plate.  Plates were incubated at 35ºC in CO2 for 18-24 hours and observed for growth.  In 
addition, a sterility control, which consisted of an uninoculated McKay agar plate, was 
incorporated with weekly QC to ensure that the McKay agar itself was not contaminated with 
bacteria or fungi during production or upon storage in the laboratory after it was received.  
Weekly QC was deemed acceptable when the prepared McKay agar supported the growth of all 
SAG ATCC strains, inhibited the growth of S. aureus (ATCC 29213), and exhibited no growth 
on the sterility plate.  All QC data was recorded in a laboratory notebook.  
Recovery and optimization of McKay agar.  Recovery studies involve inoculating known 
amounts of reference ATCC strains to agar and determining the actual quantity detected after 
incubation.  This parameter is essential when optimizing media to determine which atmospheric 
incubation condition yields the highest recovery rate of viable organisms.  The three SAG ATCC 
isolates specified above were suspended in saline to a density equivalent to a 0.5 McFarland 
standard and 10-fold serially diluted.  For each of the three ATCC strains, the 10
-4
, 10
-5
, 10
-6
, and 
10
-7
 dilutions were plated to six McKay agar plates and two blood agar plates.  The blood agar 
plates were incubated at 35°C with CO2. Two McKay agar plates for each dilution specified 
above were incubated at 35ºC with CO2, 35°C in ambient air,  and 35ºC in strict anaerobic 
(oxygen-free) conditions, respectively.  Streptococcus species are facultative anaerobes and often 
times grow better in anaerobic conditions.  In a study performed by Sibley et al. (2010), 
anaerobic incubation conditions of McKay agar was not assessed.  Further, Grinwis et al. (2010) 
conducted a six-month surveillance study in which 99 strains of SAG were isolated on McKay 
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agar.  Though aerobic and anaerobic incubation conditions were assessed, the authors did not 
comment on which was the optimal environment for growth.   
At both 18-24 hours and 48 hours of incubation under each condition, growth on the BA 
and McKay agar plates were assessed; and colonies were counted and recorded for each ATCC 
strain.  Inoculum preparations of the ATCC strains visually comparable to the density of a 0.5 
McFarland standard should contain approximately 1.5 x 10
8
 cfu/mL.  If the inoculum was 
prepared and serially diluted correctly, the 10
-6
 dilution should contain 10
2
 cfu/mL.  This verifies 
that the expected amount of organisms present remain viable and are recovered on the study 
media under varying incubation conditions.    
  Ideally, McKay agar should selectively cultivate SAG and inhibit other Streptococcal 
species and classic CF pathogens.  Media verification studies were conducted to assess the 
selective nature of McKay agar.  SAG ATCC reference strains, several Streptococcal species, 
and classic CF pathogens were inoculated to McKay agar, incubated under varying conditions, 
and observed for growth.  
Optimized incubation conditions were determined by comparing the number of 
organisms recovered to expected results, observing the appearance of the SAG colonies on each 
set of plates, and evaluating the selectivity of McKay agar.  Members of the SAG are small 
colony forming bacteria (colony size, less than or equal to 0.5 mm) on BA.  These factors were 
considered when determining the optimized incubation conditions of SAG in the study protocol.  
Anaerobes. Brucella blood agar, LKV/BBE (biplate), and PEA were used to cultivate 
anaerobes from CF respiratory samples.  The anaerobe protocol currently in place for deep 
wounds, tissues, and sinus aspirates was used for the research samples in this study (Appendix 
B).   This purchased media is prepared, stored, and dispensed under oxygen-free conditions by 
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the manufacturer which prevents formation of oxidized products.  An enzyme system, known as 
Oxyrase, is utilized by the manufacturer to specifically remove oxygen from liquids and 
semisolids.  This further ensures the media will cultivate obligate anaerobes.   
Brucella blood agar, LKV/BBE (biplate), and PEA were plated and incubated in an 
anaerobic chamber for five days.  Brucella blood agar is an enriched nonselective agar used to 
isolate obligate anaerobes from clinical specimens and contains Vitamin K and hemin in the 
medium for recovery and pigment production of Prevotella melaninogenica.  The addition of 
sheep blood in the agar allows observation of hemolytic patterns if present.   
LKV agar was used to isolate obligately anaerobic GNR.  Vancomycin is incorporated in 
this media to inhibit the growth of Gram-positive organisms, and kanamycin offers inhibition of 
facultative GNRs in clinical specimens.  Further, laked sheep blood and vitamin K1 are present in 
the agar to aid in the recovery of pigment producing anaerobes.  BBE is an enriched selective 
and differential medium used for isolating Gram-negative bacilli.  This agar contains enough 
gentamicin to inhibit the growth of most anaerobes except those belonging to the Bacteriodes 
fragilis group.  Incorporation of esculin in BBE allows esculin hydrolysis of organisms to be 
recognized by a brown to black coloration around the colonies.   
The third selective medium utilized for cultivating anaerobes was PEA.  Phenylethyl 
alcohol in the media inhibits the growth of facultative GNRs and prevents swarming of 
organisms (PRAS package insert).   Tunney et al. (2008) detected anaerobes in CF respiratory 
cultures by adding anaerobic blood agar, phenylethyl alcohol agar (PEA), and kanamycin-
vancomycin laked agar (LKV) to the routine battery of media and incubating in strict anaerobic 
conditions.    
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Culture identification of colistin-resistant non-fermenting Gram-negative rods. 
MAC and BHI agar with colistin sulfate were prepared and used in this study to select for 
emerging colistin-resistant NF GNRs in CF respiratory samples.  MAC agar is routinely used in 
clinical microbiology laboratories to select for Gram-negative rods.  This media contains bile 
salts and crystal violet which inhibits the growth of Gram-positive organisms.  There are strains 
of NF GNRs unable to grow on MAC agar; therefore, BHI agar base was also used.  Since BHI 
agar supports the growth of a wide variety of Gram-positive and Gram-negative bacteria, an 
additional antibiotic, oxalinic acid, was added to suppress the growth of normal oropharyngeal 
flora and classic CF pathogens, such as S. aureus and P. aeruginosa.  Colistin originates from 
Bacillus polymxya. Interaction of this cationic polypeptide with the outer membrane of Gram-
negative bacteria displaces calcium and magnesium which compromises the integrity of the 
cytoplasmic membrane resulting in cell lysis and death.  In addition, colistin has the ability to 
bind and neutralize endotoxins released by GNRs (Waters, 2012). 
   Kiska and Riddell (2012) cautioned laboratorians to pay close attention to any colistin- 
resistant NF GNRs isolated in CF respiratory samples, as colistin is often the last line of therapy 
used to treat multi-drug resistant strains of P. aeruginosa.  Phenotypically similar profiles among 
this group can lead to misidentification of organisms; therefore, it is recommended that any 
colistin-resistant NF GNR be identified with methods such as Matrix Assisted Laser 
Desorption/Ionization-Time of Flight (MALDI-TOF) or partial DNA sequencing.  MALDI-TOF 
is a robust identification system that speciates organisms based on a unique spectral protein 
fingerprint.  This method allows reliable identification of colistin-resistant NF GNRs despite 
their phenotypically similar profiles.  Molecular methods, such as DNA sequencing, allows 
organisms to be identified based upon genotypic rather than phenotypic characteristics.  
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Utilization of these techniques allows discrimination among the NF GNRs resulting in more 
accurate and timely identification of potential pathogens.        
  A culture enriched molecular profiling study performed by Sibley et al. (2011) revealed 
the complexity of microbial species recovered in the CF lung.  By incorporating specific media 
and altering incubation conditions, this group was able to recover almost all organisms identified 
by molecular methods in culture. The current CF culture protocol does not support the growth of 
all organisms identified by molecular analysis, such as obligate anaerobes and those obscured by 
classic CF pathogens, such as mucoid P. aeruginosa. Sibley and colleagues used media 
containing colistin sulfate to inhibit the growth of mucoid P. aeruginosa which commonly 
overgrows other organisms in routine CF culture.  BHI agar was used as a base with the addition 
of 10 mg/L of colistin sulfate and 5 mg/L of oxalinic acid.  Oxalinic acid is a quinolone 
antibiotic that has the capability to suppress the growth of Gram-positive and Gram-negative 
bacteria.  This media, supplemented with colistin and oxalinic acid prevented the growth of 
colistin-susceptible GNRs as well as Gram-positive organisms that are found in clinical samples.   
The BHI base with colistin should support the growth of I. limosus, an emerging CF 
pathogen that has yet to be recovered from CF patients at VCUMC.  BHI agar contains digests of 
gelatin and animal tissue, glucose, and brain heart infusion.  This media is particularly useful in 
cultivating fastidious aerobic and anaerobic bacteria. The colistin and oxalinic acid 
concentrations described above were used as a starting point to prepare BHI with colisitin.  In 
addition, a MAC base, which supports the growth of Gram-negative organisms, with colistin 
only was prepared.  MAC is a selective medium used to differentiate organisms based on their 
ability to ferment lactose.  Lactose-fermenting Gram-negative rods appear pink; whereas, non-
lactose fermenters appear colorless or transparent.  MAC agar contains gelatin, lactose, bile salts, 
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casein, animal tissue, neutral red, and crystal violet (Versalovic, J., 2011).  Performance of each 
media base containing colistin was evaluated.  Both prepared media types were used in the study 
protocol. 
Quality control.  Before assessing performance characteristics of the prepared colistin-
containing media, quality control (QC) was performed to ensure that the media suppressed the 
growth of colistin-sensitive isolates and supported the growth of colistin-resistant organisms.  
Five bacterial isolates were used: Escherichia coli (ATCC 25922), a colistin-susceptible NF 
GNR (patient derived strain of P. aeruginosa), colistin-resistant GNR (patient derived strain of 
Serratia marcescens), colistin-resistant NF GNR (patient derived strain of B. cepacia), S. aureus 
(ATCC 29213), and E. faecalis (ATCC 29212).  One plate of each agar base (MAC and BHI) 
containing colistin was divided into six quadrants and labeled appropriately.  A suspension of the 
above specified bacterial isolates were prepared at a density equivalent to that of a 0.5 
McFarland standard and 10 µL inoculated to each respective quadrant.  One quadrant was left 
uninoculated as a sterility control.  Plates were incubated at 35ºC in ambient air for 18-24 hours 
and observed for growth.  Expected QC results are as follows:  the MAC and BHI with colistin 
should inhibit the growth of E. coli (ATCC 25922), S. aureus (ATCC 29213), E. faecalis (ATCC 
29212) and the colistin-sensitive NF GNR (patient derived strain of mucoid P. aeruginosa) and 
support the growth of the colistin-resistant GNR (patient derived strain of S. marcescens) and 
colistin-resistant NF GNR (B. cepacia).  No growth should be observed in the sterility quadrant. 
If these expected growth patterns were observed, the prepared media passed QC.  In the event of 
a QC failure, the composition of the media was reevaluated.  Troubleshooting failed QC results 
involved adjusting the type of media and antibiotics used and the concentration of colistin sulfate 
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and oxolinic acid based on the observed growth patterns.  Optimization continued until expected 
QC results were observed.  
Performance characteristics of prepared media.  Performance of each colistin 
containing prepared medium was assessed using frozen isolates of a colistin-resistant NF GNR 
(patient derived strain of B. cepacia) and a colistin-resistant GNR (patient derived strain of S. 
marcescens).  Each of the above specified isolates were thawed, subcultured twice to BA, and 
serially diluted (ten-fold) and plated to two BHI with colistin and two MAC with colistin plates.  
One set of plates was incubated in ambient air and the other set at 35ºC with CO2.  Characteristic 
morphology, phenotypic characteristics, and limit of detection were recorded for each agar base 
and incubation condition.  Based on this data, an incubation condition for each agar base with 
colistin was selected. 
Recovery in clinical background. Media developed to screen for colistin-resistant NF 
GNR must provide visible growth of the desired organism in the presence of other organisms. 
De-identified patient sputum negative for NF GNRs was pooled for use as a diluent when 
performing serial dilutions.  This matrix contained a plethora of organisms which allowed 
specificity to be assessed.  The pool was divided and treated with a mucolytic agent, Copan 
SLsolution.  Dithiotrietal (DTT) is the active ingredient in SLsolution that liquefies sputum 
without affecting the morphology, growth, or staining of organisms.  Emulsification results in a 
homogeneous, liquid sample which allows more consistent distribution of organisms and 
reproducible planting and streaking of specimens (SLsolution Package Insert).  The processed, 
pooled aliquots were spiked with known numbers of colistin-resistant NF GNR (patient derived 
strains of A. xylosoxidans and S. marcescens) and plated to the colistin-containing media to 
assure recovery of the desired organism and inhibition of colistin-susceptible and Gram-positive 
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organisms.  The optimal incubation conditions were determined by performance characteristics 
and used in the CF research protocol.       
Specific Aim 2 
 The prevalence of emerging pathogens in the CF population at VCUMC was determined 
using optimized and verified media and incubation conditions.  Cultures were evaluated for the 
presence of emerging pathogens.  If colonies resembling targeted emerging pathogens were 
observed, they were definitively identified and recorded.  Patients culture-positive for emerging 
pathogens recovered on the study media were divided by the total number of patients during the 
study period (n=75) and multiplied by 100, which defined the prevalence of emerging pathogens 
in the CF population at VCUMC.   Upon receipt in the clinical microbiology laboratory at 
VCUMC, the respiratory samples were logged into the LIS. Once all physician-ordered tests 
were processed, inoculated, and placed in the appropriate incubation conditions, the remaining 
residual sample was stored in the refrigerator. Residual samples were retrieved from the 
refrigerator and used in the study protocol by inoculating to the following media:  BA, MAC, 
McKay agar, TSA with colistin and vancomycin, MAC with colistin, and anaerobic plates to 
include Brucella, PEA, and LKV/BBE agar.  The three anaerobic plates were immediately placed 
in an anaerobic pouch and incubated at 35ºC.  The BA and MAC agar were be placed in a 35°C 
ambient air incubator.  McKay agar, TSA with colistin and vancomycin, and MAC with colistin 
were incubated in optimized conditions according to Specific Aim 1 results (Figure 1). 
Isolation of emerging pathogens. All plates were examined on a daily basis for up to 
seven days.  Characteristic morphology and phenotypic traits of the targeted emerging pathogens 
were documented for each type of study media. The following guidelines were used when 
determining the possible presence of suspected emerging pathogens on study media:  yellow 
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colonies growing on McKay agar were subcultured and identified; any organism growing on 
colistin-containing media was subcultured, investigated, and identified; and anaerobes growing 
in greater than or equal to quantities than the classic CF pathogens were tested for aerotolerance 
(Appendix B) and identified when indicated.  Following examination, all plates were returned to 
appropriate conditions for incubation throughout the seven-day period.   
A work card, located in a laboratory notebook, was kept for each specimen documenting 
quantity (rare, growth of one to two colonies in the first quadrant; few, growth of several 
colonies in the first quadrant; moderate, growth in the second quadrant; or many, growth in the 
third quadrant), characteristic morphology, phenotypic traits, subcultures for isolation, as well as 
Gram stain and rapid test results for the presumptive identification of possible emerging 
pathogens.  Rapid biochemical tests included the following:  catalase, oxidase, indole, and PYR.  
Pure colony isolates were definitively identified by laboratorians in the clinical microbiology 
laboratory using the MALDI-TOF.  If unreliable results were achieved with this method, the 
isolate was identified by partial sequencing of its 16S rDNA.  Final organism identification was 
recorded. 
Definitive identification of emerging pathogens. Several identification techniques are 
employed in microbiology laboratories to identify organisms.  Many of the emerging pathogens 
sought in this study share similar phenotypic profiles, which can lead to the misidentification of 
organisms when using biochemical and carbohydrate utilization testing platforms.  Alternative 
methods, such as MALDI-TOF and 16S rDNA sequencing overcome this challenge by 
employing different principles that reliably and accurately identify phenotypically similar 
organisms. 
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 MALDI-TOF.  The clinical microbiology laboratory at VCUHS uses the MALDI-TOF 
method to identify bacteria isolated from clinical specimens (Appendix C).  MALDI-TOF 
provides a protein spectrum fingerprint of cultured organisms by separating and detecting 
ionized proteins by their mass/charge ratio.  Each ion detected is characterized by the following:  
molecular mass, charge, mass/charge ratio, and signal intensity.  From these data, a unique 
profile of the bacterial components is constructed.  Comparison of the spectrum of proteins 
generated during laser desorption is made against a database library of reference strains to 
identify the organism.  Reproducibility of this method is attributed to the measurement of high 
abundance ribosomal proteins which is unaffected by variability in environmental or growth 
conditions.  Identification of cultured organisms can be obtained in minutes at a low cost 
(Carbonnell et al., 2011; Fernandez-Olmos et al., 2012).  Kiska and Riddell (2012) described a 
study in which MALDI-TOF was used to identify 558 strains of glucose NF GNRs.  This method 
correctly identified 98% of those isolates which consisted of 58 separate species and 
approximately 52 BCC isolates.  Many microbiologists have suggested that MALDI-TOF be 
used as the gold standard for CF isolate identification with confirmation by partial 16S rRNA 
sequencing when necessary (Bittar & Rolain, 2010). 
 Sequencing.  Partial 16S rDNA sequencing is used in the clinical microbiology 
laboratory to identify rare bacteria, slow-growing bacteria, organisms that do not match 
recognized phenotypic profiles, and organisms that yield a poor or no identification by 
commercial systems or MALDI-TOF.  Universal primers anneal to conserved regions of the 
bacterial rRNA gene.  During dye terminator cycle sequencing, variable regions generate unique 
nucleotide base sequences that are species-specific.  Capillary electrophoresis, carried out in an 
automated DNA sequencer, is conducted for size separation, detection and recording of dye 
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fluorescence, and data output as fluorescent peak trace electropherograms.  These are 
downloaded to SmartGene software, manually analyzed, and compared to reference sequences in 
a curated database to determine organism identification. 
Prevalence.  Prevalence is defined as the proportion of a population found to have a 
condition.  For the purpose of this study, the population consisted of 75 CF patients in which 
respiratory specimens were submitted to the clinical microbiology laboratory at VCUHS, and the 
condition is the presence of emerging pathogens isolated in culture.  Because there are no means 
to indicate whether a particular emerging pathogen was present in previous cultures, prevalence, 
which includes both new and old cases, is preferable to incidence, for this study.  Prevalence was 
calculated as follows: 
Prevalence = Patients culture-positive for emerging pathogens     x 100 
                      Total number of patients during study period 
 
 The prevalences of each group of targeted emerging pathogens (SAG, anaerobes, and 
colistin-resistant NF GNRS) were calculated separately. A specimen was classified as positive 
for emerging pathogens if a single colony of SAG or colistin-resistant NF GNRs was recovered 
in culture.  Specimens were classified positive if anaerobes were present in equal or greater 
quantities than the principal pathogens.  In addition to prevalence, organisms falling into each 
category of emerging pathogens were identified to the species level.  
 Access to all routine microbiology culture data results through Cerner, the laboratory 
information system, was requested for residual specimens used in the study. This allowed 
comparison of the routine and research culture protocol (Specific Aim 3).  The routine CF 
culture protocol (Appendix A) detected the classic CF pathogens known to play a role in CF lung 
disease.  The research protocol utilized McKay agar, anaerobic media, and the colistin-
containing agar to select for targeted emerging pathogens.  In addition, access to Cerner enabled 
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the researcher to match respiratory samples with patient identifiers. This was necessary in order 
to ensure that at least 50 separate patients were sampled during the study period. In addition, if a 
patient was sampled more than once during the study period, culture review allowed matching 
multiple culture results to the appropriate patient. This was accomplished by tracking the 
accession number generated when the culture was ordered and logged into the clinical 
microbiology laboratory.   
Specific Aim 3 
Specific aim 3 was accomplished by prospectively evaluating the current CF culture 
procedure with the research protocol to identify discrepant results.  Traditional CF cultures were 
evaluated and reported by clinical laboratory scientists in the clinical microbiology laboratory at 
VCUMC.  These results were entered into Cerner, the laboratory information system.  Culture 
results included pathogens or potential pathogens isolated in clinical specimens and their 
corresponding antimicrobial susceptibility profiles. The final culture results were obtained for 
each residual respiratory sample included in the study and compared to the results of the research 
study including organisms subcultured for purity, results of rapid tests, and unique phenotypic or 
morphologic traits.  A final organism ID, obtained by MALDI-TOF, was provided for any 
targeted emerging pathogen isolated on the additional media incorporated for this study protocol.    
Any culture that was positive for the presence of emerging pathogens using the research protocol 
was earmarked.  If more than one culture was submitted for an individual patient, culture results 
were compared over more than one data point.  
Conclusion 
In summary, Chapter 3 presented the materials and methods employed to accomplish the 
goal and specific aims of the study.  The validation and implementation of McKay agar targeting 
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members of the SAG was described.  The development, optimization and implementation of a 
culture-dependent screening method for colistin-resistant GNRs was discussed, and protocols 
used to cultivate anaerobes in the respiratory samples of CF patients was presented.  In addition, 
analyses used to determine prevalence of emerging pathogens in CF patients at VCUMC and 
methods to prospectively evaluate routine and research protocol culture results were delineated.        
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Chapter 4:  Results 
 
Introduction 
The purpose of this study was to expand the use of microbiology culture strategies to 
improve management and treatment of CF patients at VCUMC.  Results obtained are described 
and reported based on each of the accomplished specific aims.  Specific Aim 1 results focus on 
the development, optimization, and implementation of culture-dependent screening protocols 
used to detect SAG, anaerobes, and colistin-resistant NF GNR in the CF population at VCUMC.  
Results of Specific Aim 2 provide a summary of the CF population studied as well as the 
respiratory samples used to determine the prevalence of emerging pathogens.  Specifically, 
patient demographics and sample characteristics are described.  In addition, the prevalences of 
emerging pathogens in the CF population at VCUMC is reported.  Lastly, results from the study 
protocol are highlighted and compared to those obtained using CF Foundation recommended 
culture techniques. 
Specific Aim 1 
 Specific Aim 1 was accomplished by developing, optimizing, and implementing or 
incorporating previously-developed, culture-dependent screening protocols to detect the 
following emerging CF pathogens:  members of the SAG (McKay agar), anaerobes (Brucella,  
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PEA, BBE/LKV), and colistin-resistant NF GNR (MAC with colistin and TSA with colistin and 
vancomycin).  Table 3 provides a summary of how this aim was accomplished.   
 
Table 3. Development, Optimization and Validation of Study Media 
 
Targeted 
Emerging 
Pathogens 
Media Quality Control 
Organisms/Expected 
Results 
Media Studies for 
Optimization/Valid
ation 
SAG McKay agar S. anginosus (ATCC 33397) 
(+) 
S. intermedius (ATCC 
27335) (+) 
S. constellatus (ATCC 
27823) (+) 
S. aureus (ATCC 29213) (-) 
Sterility (-) 
Recovery 
 
 
Media Verification 
Anaerobes Brucella 
PEA 
BBE/LKV 
CLSI-exempt from QC N/A 
Colistin-resistant 
NF GNR 
Agar bases  
 
 BHI/TSA 
with 
colistin/  
vancomycin 
 
 MAC with 
colistin 
 
E. coli (ATCC 25922) (-) 
P. aeruginosa (-) 
S. marcescens (+) 
B. cepacia (+) 
S. aureus (ATCC 29213) (-) 
Sterility (-) 
Recovery 
 B. cepacia 
and S. 
marcescens 
 
Recovery in Clinical 
Background 
 A. 
xylosoxidans  
S. 
marcescens 
 
 
 
+=growth, -=no growth 
 
Identification of SAG with McKay agar.  In this study, SAG were specifically targeted 
as emerging CF pathogens; therefore, McKay agar (Sibley et al., 2008) was incorporated into the 
research protocol.  Using the previously published formula for McKay agar, custom agar plates 
were prepared by Teknova Inc. and shipped to the clinical microbiology laboratory at VCUMC.  
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Quality control testing, limit of detection, performance characteristics, and media verification 
were performed on McKay agar to ensure suitability for use in the study protocol.   
 Quality control.  Upon arrival, and weekly thereafter, throughout the duration of the 
study period, quality control testing was performed on McKay agar with the following 
organisms:  S. anginosus (ATCC 33397), S. intermedius (ATCC 27335), S. constellatus (ATCC 
27823), and S. aureus (ATCC 29213).  A sterility plate was also included each time quality 
control was performed.  The agar plates were deemed acceptable if all of the following were 
observed:  growth of S. anginosus (ATCC 33397), S. intermedius (ATCC 27335), and S. 
constellatus (ATCC 27823) on McKay agar, which was indicated by the formation of yellow 
colonies on the media; and absence of growth of S. aureus (ATCC 29213) on McKay agar.  The 
sterility control, which consists of an uninoculated McKay agar plate, was incubated and 
expected to exhibit no growth. The McKay agar plates passed QC each time, throughout the 
duration of the study period. 
 Recovery and performance characteristics of McKay agar.  To determine the optimized 
incubation condition for McKay agar in this study, recovery and performance characteristics 
were assessed and compared to those on BA under the following incubation conditions:  35°C 
ambient air, 35°C CO2, and 35°C anaerobic conditions.  When cultivating SAG isolates in a 
clinical laboratory, optimal growth is achieved when organisms are subcultured to BA and 
incubated at 35°C with CO2; therefore, this was considered the standard to which all McKay agar 
data, with regard to recovery and performance characteristics, were compared.  In addition, 
members of the SAG grow as pinpoint colonies on BA, produce a buttery or caramel smell, and 
vary in regard to hemolytic patterns.  These documented growth characteristics were recorded 
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and used to compare and contrast those observed on McKay agar for each of the three SAG 
strains. 
 Recovery was determined by preparing 0.5 McFarland turbidity standard suspensions of 
the following:  S. anginosus (ATCC 33397), S. intermedius (ATCC 27335), and S. constellatus 
(ATCC 27823).    The prepared 0.5 McFarland standard suspensions of each respective SAG 
isolate were 10-fold serially diluted, subcultured to solid media in duplicate, and incubated for 48 
hours in the following:  35°C ambient air, 35°C CO2, and 35°C anaerobic conditions.  Colonies 
observed on solid media at each dilution were counted after 24 and 48 hours of incubation, 
averaged, and recorded.  Based on results of the recovery study (Table 4), it was determined that 
anaerobic incubation conditions were optimal for recovering all three members of SAG.  An 
increased number of SAG colonies were recovered on McKay agar under anaerobic conditions 
when compared with aerobic or aerobic with CO2 atmospheric incubation conditions.  As 
indicated by the recovery study, aerobic conditions (35°C) should not be used to cultivate SAG.  
S. intermedius (ATCC 27335) and S. constellatus (ATCC 27823) did not yield any observable 
colonies on McKay agar after 48 hours of incubation under aerobic atmospheric conditions.  
In addition, after 48 hours, SAG colonies were larger in size under anaerobic conditions than the 
typical pinpoint size colonies seen on BA, and in this case, McKay agar at 35°C in CO2.  The 
characteristic buttery or caramel smell of SAG isolates on BA was not noted with McKay agar.  
Also, hemolytic patterns could not be assessed on McKay agar.   
In order to ensure that the prepared 0.5 McFarland standard suspensions of each organism 
fell within the acceptable range (1-2 x 10
8
 cfu/mL),  final colony counts from the original 
inoculum were calculated from the BA plates incubated for 48 hours at 35°C in CO2 and  
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Table 4. Average Colony Counts of SAG on McKay Agar 
 
Incubation 
Conditions 
Colony Counts 
(cfu/mL) 
Aerobic CO2 
35°C 
Colony Counts 
(cfu/mL) 
Aerobic 
35°C 
Colony Counts 
(cfu/mL) 
Anaerobic 
35°C 
Dilution 
Factors 
10
-6
 10
-7
 10
-8
 10
-6
 10
-7
 10
-8
 10
-6
 10
-7
 10
-8
 
S. intermedius 64 20 1 0 0 0 134 21 2 
S. constellatus 59 12 2 0 0 0 112 19 2 
S. anginosus 132 9 2 112 8 2 158 12 2 
  
compared to expected results.  Based on these data (Table 5), it was confirmed that the 0.5 
McFarland standard suspensions of each organism were prepared and serially diluted correctly.  
    
Table 5. Average Colony Counts of SAG Isolates on BA 
 
Incubation 
Conditions 
Average 
Colony Counts 
Aerobic CO2 
35°C 
Organisms 
(cfu/mL) 
Dilution 
Factors 
10
-6
 10
-7
 10
-8
  
S. intermedius 61 19 2 1.9 x 10
8
 
S. constellatus 75 18 2 1.8 x 10
8
 
S. anginosus 141 10 2 1.0 x 10
8
 
 
 Media verification. The specificity of McKay agar for SAG in the presence of other 
organisms was determined.  Ten de-identified respiratory samples, consisting of four Eswabs and 
six sputa, were plated to McKay agar and incubated for 24 hours at 35°C under anaerobic 
conditions.  After 24 hours of incubation, the plates were observed for the presence of possible 
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SAG, which produce yellow colonies on McKay agar.  Scant growth was observed; therefore, 
the plates were reincubated for an additional 24 hours.  After a total of 48 hours of incubation, 
growth on McKay agar revealed several different morphotypes of yellow colonies, varying in 
size and texture.  All colony types were subcultured to BA, incubated for 24 to 48 hours at 35°C 
in CO2, and identified using MALDI-TOF.  Members of SAG were recovered; however, it 
appeared as though other members of the viridans streptococci, which are also considered normal 
oropharyngeal flora, were able to produce an acid environment on McKay agar, resulting in a 
color change of the media.   
 Due to the unexpected results obtained during respiratory matrix testing, pure isolates of 
several organisms that could possibly be encountered in CF respiratory samples, such as SAG 
and other members of the viridans streptococci, S. aureus (ATCC 29213), and NF GNRs were 
selected and tested.  A 0.5 McFarland standard suspension of each organism was prepared and 
ten microliter aliquots were inoculated to assigned quadrants on McKay agar.  Three sets of 
plates were inoculated in an identical fashion, and incubated for 48 hours under the following 
conditions:  35°C, 35°C with CO2, and 35°C in an anaerobic environment.  The selected 
organisms and results obtained under each of the above specified incubation conditions are listed 
in Table 6.   
In addition to SAG, many species of viridans streptococci, which are considered normal 
respiratory flora, produced yellow colonies on McKay agar, especially when incubated under 
anaerobic conditions, which is optimal for recovering SAG.  Based on these findings, it was 
evident that McKay agar could only be used to screen CF respiratory samples for the presence of 
SAG.  Any yellow colony growing on McKay agar, regardless of size and texture, should be 
subcultured to BA and identified by MALDI-TOF.   
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Table 6:  McKay Agar Specificity Testing 
Organism Aerobic 
35°C 
Aerobic CO2 
35°C 
Anaerobic 
35°C 
S. aureus  
(ATCC 29213) 
No growth No growth No growth 
E. coli 
(ATCC 25922) 
No growth No growth No growth 
S. anginosus 
(ATCC 33397) 
Growth 
Yellow colonies 
Growth 
Yellow colonies 
Growth 
Yellow colonies 
S. constellatus 
(ATCC 27823) 
No growth Growth 
Yellow colonies 
Growth 
Yellow colonies 
S. intermedius 
(ATCC 27335) 
No growth Growth 
Yellow colonies 
Growth 
Yellow colonies 
S. mitis 
(patient derived) 
Growth 
No yellow colonies 
Growth 
No yellow colonies 
Growth 
Yellow colonies 
S. parasanguinis 
(patient derived) 
Growth 
Yellow colonies 
Growth 
Yellow colonies 
Growth 
Yellow colonies 
S. salivarius 
(patient derived) 
Growth 
Yellow colonies 
Growth 
Yellow colonies 
Growth 
Yellow colonies 
S. oralis 
(patient derived) 
Growth 
No yellow colonies 
Growth 
No yellow colonies 
Growth 
Yellow colonies 
P. aeruginosa 
(ATCC 27853) 
No growth No growth No growth 
P. aeruginosa 
(mucoid) 
(patient derived) 
No growth No growth No growth 
B. cepacia 
(patient derived) 
No growth No growth No growth 
A. xylosoxidans 
(patient derived) 
No growth No growth No growth 
  
McKay agar inhibited the growth of S. aureus (ATCC 29213) and many NF GNRs 
routinelyfound in CF cultures.  In the routine culture protocol, SAG would be obscured by these 
organisms, preventing the isolation and identification of these emerging pathogens.  Therefore, 
the addition of McKay agar as a culture-dependent screening method for SAG was warranted. 
Anaerobes. Three agar plates, Brucella, PEA, and LKV/BBE, were added to the research 
protocol for cultivation and isolation of strict anaerobes from CF sputum samples.  The standard 
operating procedure currently in place for deep wounds, tissues, and sinus aspirates was followed 
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when incubating, cultivating, and identifying strict anaerobes from research samples in this 
study. (Appendix B). After 48 hours of incubation at 35°C under anaerobic conditions, growth 
on Brucella, PEA, and LKV/BBE was compared to growth on the BA incubated at 35°C in 
ambient air.  This aided in the determination of true obligate aerobes versus facultative 
anaerobes.  An aerotolerance test was performed on suspected obligate aerobes that were in 
quantities greater than or equal to the principal CF pathogens.  If results of the aerotolerance test 
indicated that the organism was a true obligate anaerobe by only growing in strict anaerobic 
conditions, the isolate was definitively identified using MALDI-TOF.  All of the obligate 
anaerobes reported in this study were adequately cultivated and isolated on Brucella agar.  Based 
on this observation, the PEA and LKV/BBE agars were not necessary to cultivate this group of 
emerging pathogens.  Eliminating these additional agars would decrease the cost and labor 
intensiveness in future studies.   
Culture identification of colistin-resistant non-fermenting Gram-negative rods. Two 
types of agar containing colistin sulfate were developed, optimized, and implemented in the 
study protocol to select for emerging colistin-resistant NF GNRs.  MAC containing colistin was 
optimized and validated for use with recovery studies.  The second agar base, BHI, which 
contained colistin and oxalic acid, repeatedly failed quality control testing by not inhibiting the 
growth of S. aureus (ATCC 29213).  In addition, the agar did not suppress the growth of Gram-
positive OF when challenged with clinical matrix (respiratory samples).  As a result, an 
alternative agar base, Tryptic Soy Agar (TSA), was selected and validated for use in the study.  
Oxalinic acid was replaced with vancomycin to sufficiently suppress the growth of normal OF 
when selecting for colistin-resistant NF GNRs in CF respiratory samples.   
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Several batches of MAC and BHI agar with varying concentrations of colistin were 
prepared and tested to determine the optimal concentration for use in the study.  Initially, the 
following concentrations of colistin were prepared, sterilized, and incorporated into the MAC 
and BHI agar bases:  2.5 mg/L, 5 mg/L, 10 mg/L, 20 mg/L, and 40 mg/L.   
Quality control was performed on all concentrations of each media type which consisted 
of E. coli (ATCC 25922), S. aureus (ATCC 29213), and a patient derived strains of B. cepacia, 
P. aeruginosa, and S. marcescens.  These organisms were also used to inoculate both BHI and 
MAC plates which contained no colistin.  Sterility plates were also incubated.  Expected QC 
results for each media type were observed after 48 hours of incubation at 35°C.  The sterility 
plates exhibited no growth, all isolates grew on BHI and MAC with no colistin, indicating the 
organisms were viable. B. cepacia and S. marcescens grew on all BHI and MAC at all colistin 
concentrations, and E. coli, P. aeruginosa, and S. aureus (ATCC 29213) did not grow on any of 
the colistin-containing media. 
     Seventy-four clinically-derived GNRs, with known colistin susceptibility results 
(Table 7), were used to determine the optimal colistin concentration for use in the study.  Fresh 
subcultures were used to prepare 0.5 McFarland standard suspensions of each isolate, and 10 
microliters were dispensed onto the respective MAC and BHI plates containing various 
concentrations of colistin. All plates were incubated at 35°C and read at 24 and 48 hours.  
Results revealed that all colistin-resistant isolates (n=21) grew on either MAC or BHI with 20 
mg/L of colistin, five colistin-sensitive strains grew on  MAC or BHI with 10 mg/L, and the BHI 
plate which contained 20 mg/L and 40 mg/L of colistin inhibited the growth of one colistin-
resistant strain.  In summary, MAC and BHI with 10 mg/L was not inhibitory enough; however,  
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Table 7. Isolates Used for Initial Determination of Optimal Colistin Concentration for MAC and 
BHI 
Organism Colistin 
Sensitive 
Colistin 
Resistant 
Total 
Achromobacter xylosoxidans 6 7 13 
Acinetobacter baumanni 6 0 6 
B. cenocepacia 0 1 1 
B. cepacia 0 1 1 
B. gladioli 0 1 1 
Chryseobacterium indologenes 0 2 2 
Inquilinus limosus 0 1 1 
Myroides odoratus 0 1 1 
Pseudomonas aeruginosa 19 0 19 
Pseudomonas aeruginosa 
(mucoid) 
9 0 9 
Ralstonia pickettii 0 1 1 
Serratia marcescens 0 4 4 
Sphingobacterium spiritivorum 0 2 2 
Stenotrophomonas maltophilia 13 0 13 
Total 53 21 74 
   
20 and 40 mg/L was too inhibitory; therefore, an additional concentration of colistin (15 mg/L), 
was tested. 
Thirty-nine of the 74 clinical isolates (Table 8) used in the previous concentration study, 
representing a mixture of colistin-sensitive and colistin-resistant GNRs, were selected for repeat 
testing on BHI and MAC containing the following colistin concentrations: 10 mg/L, 15 mg/L, 
and 20 mg/L of colistin.  QC was performed as described above and expected results were 
observed.  The 39 clinically derived isolates were prepared as previously described, incubated at 
35°C, and read at 24 and 48 hours.  One colistin-sensitive strain of S. maltophilia grew on BHI 
with 10 mg/L of colistin and one colistin-resistant strain of M. odoratus was inhibited by 20 
mg/L of colistin. These data revealed that 15 mg/L was the optimal concentration of colistin to 
incorporate into both MAC and BHI agar bases to select for colistin-resistant NF GNR in CF 
respiratory samples. 
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Table 8:  Isolates Used for Follow-Up Determination of Optimal Colistin Concentration for 
MAC and BHI 
Organism Colistin 
Sensitive 
Colistin 
Resistant 
Total 
Achromobacter xylosoxidans 2 3 5 
Acinetobacter baumanni 5 0 5 
B. cenocepacia 0 1 1 
B. cepacia 0 1 1 
B. gladioli 0 1 1 
Chryseobacterium indologenes 0 2 2 
Inquilinus limosus 0 1 1 
Myroides odoratus 0 1 1 
Pseudomonas aeruginosa 8 0 8 
Pseudomonas aeruginosa 
(mucoid) 
4 0 4 
Ralstonia pickettii 0 1 1 
Serratia marcescens 0 2 2 
Sphingobacterium spiritivorum 0 1 1 
Stenotrophomonas maltophilia 6 0 6 
Total 25 14 39 
     
 BHI agar with colistin and oxalinic acid.  Once the optimal concentration of colistin 
was determined to select for colistin-resistant NF GNRs, oxalinic acid was then incorporated into 
the BHI to inhibit the growth of Gram-positive organisms.  Sibley et al. (2011) added 5 mg/L of 
oxalic acid to achieve desired suppression of Gram-positive organisms.  Using this as a starting 
point, BHI agar with the following concentrations of oxalinic acid were prepared:  2.5 mg/L, 5 
mg/L, and 10 mg/L.  Two Gram-positive organisms, S. aureus (ATCC 29213) and E. faecalis 
(ATCC 29212), and one colistin-resistant NF GNR, B. cepacia were used for quality control.  
Both ATCC strains grew on BHI agar with all concentrations of oxalinic acid and B. cepacia was 
suppressed.  Additional BHI plates were prepared with 15 mg/L of colistin and 2.5 mg/L, 5 
mg/L, and 10 mg/L of oxalinic acid.  QC was performed, and the same results were observed.   
Media verification. De-identified respiratory samples were plated to BHI agar with  15 
mg/L of colistin and oxalinic acid and BHI containing oxalinic acid alone to determine if other 
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members of the OF would be inhibited.  After a total of 48 hours of incubation at 35°C, it was 
evident that oxalinic acid did not sufficiently inhibit the growth of other Gram-positive 
organisms such as members of the viridans streptococci and Corynebacterium spp., both 
considered normal respiratory flora.   
BHI with vancomycin.  Based on the poor performance of oxalic acid in BHI agar, a 
glycopeptide, vancomycin, was selected to suppress the growth of Gram-positive organisms.  A 
stock solution of vancomycin was prepared and diluted to make BHI agar plates with the 
following concentrations:  1 mg/L, 1.5 mg/L, 2 mg/L, 2.5 mg/L, 3 mg/L and 4 mg/L.  Quality 
control was performed on each BHI plate at the above concentrations using the following 
organisms:  S. aureus (ATCC 29213), E. faecalis (ATCC 29212), and E. faecalis (ATCC 51299).  
After 24 hours of incubation at 35°C, results were observed and recorded.  All isolates grew on 
each BHI plate with all vancomycin concentrations demonstrating that this media was not 
suppressing the growth of Gram-positive organisms, as desired.  The calculations used to prepare 
the stock solution of vancomycin and agar plates containing the varying concentrations were 
checked for accuracy.   
After confirming that the calculations were correct, a fresh stock solution of vancomycin 
was prepared and used to prepare another batch of BHI with vancomycin at the above stated 
concentrations.  The temperature of the BHI agar was allowed to cool to 50°C before adding the 
vancomycin to ensure that the antibiotic was not heat inactivated.  Fresh isolates of the 
organisms listed above were used for QC testing.  After 24 hours of incubation at 35°C, the same 
results were observed as with the previous batch of media.   
At this point, vancomycin was purchased from a different manufacturer for testing. Upon 
arrival in the laboratory, a stock solution of vancomycin was made and BHI plates with varying 
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concentrations of vancomycin were prepared as described above, with the addition of three more 
vancomycin concentrations, 6 mg/L, 8 mg/L, and 20 mg/L.  The same QC organisms and 
incubation conditions were used to assess the agar.  Once again, the same results were obtained.  
At this point it was suspected that the vancomycin may be binding to some component of the 
agar and is not available to suppress the growth of vancomycin-susceptible organisms.  In order 
to test this theory, vancomycin Etests were performed on two isolates, S. aureus (ATCC 29213) 
and E. faecalis (ATCC 29212).  Two bases were used to test these isolates.  BHI agar without 
vancomycin and Mueller-Hinton (MH) agar were prepared, which is routinely used for 
susceptibility testing in the clinical laboratory.  All Etests were incubated for 24 hours at 35°C.  
The minimum inhibitory concentrations (MIC) for S. aureus (ATCC 29213) and E. faecalis 
(ATCC 29212) on BHI were 6 ug/mL and 12 ug/mL, respectively.  The vancomycin MICs on 
MH agar for S. aureus (ATCC 29213) and E. faecalis (ATCC 29212) were 1 ug/mL and 3 
ug/mL, respectively, which were within expected ranges.  These results supported the suspicion 
that vancomycin was binding to some component in the BHI agar.  As a result, an alternative 
agar base, Tryptic Soy agar (TSA) was selected for use in the study.    
TSA agar with vancomycin.  Tryptic soy agar was selected as an alternative to BHI agar.  
A stock solution of vancomycin was prepared, sterilized, and diluted to achieve TSA agar plates 
with the following concentrations:  1 mg/L, 1.5 mg/L, 2 mg/L, 2.5 mg/L, 3 mg/L, 4 mg/L, 6 
mg/L, and 8 mg/L.  Three organisms, S. aureus (ATCC 29213), E. faecalis (ATCC 29212), and 
E. faecalis (ATCC 51299) were selected for QC.  The QC organisms were prepared and 
inoculated to the TSA agar with varying vancomycin concentrations.  After 24 hours of 
incubation at 35°C, plates were observed for growth.  Expected results were observed; this agar 
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suppressed the growth of S. aureus (ATCC 29213) and E. faecalis (ATCC 29212), and supported 
the growth of E. faecalis (ATCC 51299).    
Five de-identified respiratory samples were used for matrix testing.  TSA agar plates with 
the following concentration of vancomycin were prepared and used:  2 mg/L, 4 mg/L, 6 mg/L, 
and 8 mg/L.  Each respiratory sample was plated to TSA without vancomycin, and TSA agar 
plates containing the concentrations listed above.  After a total of 48 hours of incubation at 35°C, 
it was evident that vancomycin inhibited Gram-positive organisms and normal OF.  However, 
scant growth was still seen on the TSA agar containing 8 mg/L of vancomycin.  A Gram stain of 
colonies growing on TSA with 8 mg/L of vancomycin revealed Gram-positive rods and Gram-
negative diplococci, both normal members of OF.  Since the purpose of this media was to inhibit 
these types of organisms, testing TSA with a higher concentration of vancomycin was warranted.  
As a result, TSA with 16 mg/L of vancomycin was prepared.  QC was performed on TSA with 
16 mg/L of vancomycin and expected results were observed.  This media inhibited the growth of 
S. aureus (ATCC 29313) and E. faecalis (ATCC 29212) and supported the growth of E. faecalis 
(ATCC 51299).  An additional five de-identified respiratory samples were used and matrix 
testing was repeated.  Normal flora was abundant in all five samples on the TSA plate without 
vancomycin and completely inhibited on the TSA plate with 16 mg/L of vancomycin after 48 
hours of incubation.  Based on these results, it was determined that 16 mg/L of vancomycin was 
the optimal concentration needed to inhibit the growth of Gram-positive organisms and OF.   
TSA agar with colistin.  Since BHI was replaced with TSA, the optimal concentration of 
colistin needed to select for colistin-resistant NF GNRs needed to be determined.  The 74 isolates 
listed in Table 7 were used to test TSA with colistin at the following concentrations:  2.5 mg/L, 5 
mg/L, 10 mg/L, 20 mg/L, and 40 mg/L.  Testing was performed in the same manner as 
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previously described with MAC agar.  Similar results were obtained.  Some colistin-sensitive 
isolates, such as P. aeruginosa, grew on TSA with 10 mg/L of colistin; many of the colistin-
resistant isolates were inhibited at 40 mg/L; and M. odoratus, a colistin-resistant NF GNR, was 
inhibited at a colistin concentration of 20 mg/L.  To narrow down the optimal colistin 
concentration, a subset of the 74 isolates (Table 8) was used to test TSA with the following 
colistin concentrations:  10 mg/L, 15 mg/L, and 20 mg/L.  As seen with BHI agar, a few colistin-
sensitive strains grew at 10 mg/L and M. odoratus was inhibited at 20 mg/L of colistin in TSA.  
Therefore, 15 mg/L was determined to be the optimal concentration of colistin in TSA to select 
for colistin-resistant NF GNR in CF respiratory samples.   
TSA agar with colistin and vancomycin.  The optimal concentration of colistin (15 
mg/L) and vancomycin (16 mg/L) in TSA were determined separately.  Therefore, TSA plates 
containing optimal concentrations of both antibiotics were prepared and tested to ensure 
expected results were achieved.  Quality control organisms for this prepared media consisted of 
the following:  S. aureus (ATCC 29213), E. faecalis (ATCC 29212), E. faecalis (ATCC 51299), 
E. coli (ATCC 25922), and a patient derived strain of B. cepacia.  QC organisms were prepared 
and tested as previously described.  After 24 hours of incubation the agar suppressed the growth 
of all QC organisms, except E. faecalis (ATCC 51299) and the patient derived strain of B. 
cepacia, indicating that the agar was functioning as desired.  
The TSA plates with 15 mg/L of colistin and 16 mg/L of vancomycin were used to test 
the organisms in Table 7.  This was performed to ensure that none of the colistin-resistant NF 
GNR were inhibited by the addition of vancomycin.  The TSA with colistin and vancomycin 
suppressed the growth of colistin-sensitive isolates and supported the growth of colistin-resistant 
isolates. In addition, five de-identified respiratory samples were plated to TSA without colistin 
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and vancomycin and TSA with 15 mg/L of colistin and 16 mg/L of vancomycin.  After a total of 
48 hours of incubation at 35°C, growth was observed on TSA without antibiotics, and growth 
was suppressed on TSA with colistin and vancomycin.  Results indicated that Gram-positive 
organisms and normal respiratory flora were inhibited as desired.   
Performance characteristics of MAC with colistin and TSA with vancomycin and 
colistin.  Two patient derived colistin-resistant strains of B. cepacia and S. marcescens were used 
to assess the performance characteristics of MAC with colistin and TSA with vancomycin and 
colistin.  McFarland standard suspensions (0.5) of each organism was prepared and 10-fold 
serially diluted.  One-hundred microliters of the 10
-5
, 10
-6
, and 10
-7
 dilutions were plated to four 
MAC with colistin plates and four TSA with vancomycin and colistin plates.  One set of plates 
(two of each respective type for each respective organism) was incubated in ambient air and the 
other at 35°C with CO2.  Plates were removed and visually inspected at both 24 and 48 hours, at 
which time colonies were counted and recorded (Tables 9 and 10).   
 
Table 9. Performance Characteristics of MAC with Colistin 
 
 
Incubation 
Conditions 
Colony Counts 
(cfu/mL) 
Aerobic CO2 
35°C 
Colony Counts 
(cfu/mL) 
Aerobic 
35°C 
Dilution 
Factors 
10
-6
 10
-7
 10
-8
 10
-6
 10
-7
 10
-8
 
B. cepacia 90 19 1 86 19 1 
S. marcescens 95 14 1 102 20 1 
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Table 10. Performance Characteristics of TSA with Colistin and Vancomycin 
 
 
Incubation 
Conditions 
Colony Counts 
(cfu/mL) 
Aerobic CO2 
35°C 
Colony Counts 
(cfu/mL) 
Aerobic 
35°C 
Dilution 
Factors 
10
-6
 10
-7
 10
-8
 10
-6
 10
-7
 10
-8
 
B. cepacia 90 19 1 94 26 1 
S. marcescens 98 15 1 99 47 2 
 
Due to size of the organisms, the plates inoculated with B. cepacia had to be incubated for an 
addition 24 hours in order to accurately count colonies on the agar.  There was no difference in 
incubation conditions with regard to colonies counted or characteristic morphology of the tested 
organisms.  Therefore, 35°C was selected as the atmospheric incubation condition used in this 
study.  Similarly, MAC plates used in the routine CF protocol are also incubated at 35°C without 
CO2.   
Media verification.  Both TSA with colistin and vancomycin and MAC with colistin 
were developed to screen for colistin-resistant NF GNRs in CF respiratory samples.  In order to 
assess their specificity, de-identified patient respiratory samples were pooled and used as a 
diluent when performing serial 10-fold dilutions.  Two patient derived colistin-resistant isolates, 
A. xylosoxidans and S. marcescens were prepared and serially diluted.  One-hundred microliters 
of the 10
-5
, 10
-6
, and 10
-7
 dilutions were plated to MAC with colistin and TSA with colistin and 
vancomycin as described above.  At both 24 and 48 hours of incubation at 35°C, plates were 
removed and colonies were counted.  Expected recovery of organisms was achieved (Table 11), 
and Gram-positive organisms and normal OF flora were inhibited.  The colistin-containing 
media was validated for use in the study protocol. 
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Table 11. Media Verification of MAC with Colistin and TSA with Colistin and Vancomycin 
 
 
Media Type 
MAC w/ Colistin 
(cfu/mL) 
35°C 
TSA w/ Colistin 
and Vancomycin 
(cfu/mL) 
35°C 
Dilution 
Factors 
10
-6
 10
-7
 10
-8
 10
-6
 10
-7
 10
-8
 
A. xylosoxidans 83 15 0 79 11 1 
S. marcescens 91 17 0 96 11 1 
 
Preliminary trial and study protocol. Once all media had been developed, optimized, and 
validated, a test run of the study was completed.  Over a two-week period, a total of 10 de-
identified CF respiratory samples were plated to routine and study media.  This was performed to 
develop a workflow and procedure for culture workup during the study period (Table 12).  
Table 12. Research Study Protocol for Culture Workup 
 
Media Study Protocol 
McKay Agar  Incubate for 48 hours in anaerobic conditions 
(35°C) 
 Subculture any yellow colonies to BA 
 Send colonies resembling SAG to MALDI for ID 
MacConkey w/ Colistin  Incubate for 48 hours in aerobic conditions (35°C) 
 Subculture any GNR to BA 
 Send to MALDI for ID 
TSA w/ Colistin and 
Vancomycin 
 Incubate for 48 hours in aerobic conditions (35°C) 
 Subculture any colony resembling GNR to BA 
 Confirm colony morphology on BA as GNR with 
GS 
 Send to MALDI for ID 
Brucella, PEA, BBE/LKV  Incubate for 48 hours in anaerobic conditions 
(35°C) 
 Observe plates for growth of anaerobes by 
comparing to growth on BA 
 Perform aerotolerance test on any suspected 
anaerobe 
 Send strict anaerobes to MALDI for ID 
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Specific Aim 2 
 The prevalence of emerging pathogens in the CF population at VCUMC was determined 
based on culture results obtained from utilizing the optimized and validated media.   
Population and sample. During the study period, 101 CF respiratory samples from a 
total of 75 (38 females, 37 males) patients were tested.  The residual CF respiratory samples 
included in the study originated from 35 adult and 40 pediatric patients.  The average age in the 
adult population, defined as those ≥18 years of age, was 28.37 years.  The pediatric population 
was defined as patients <18 years of age, with a mean of 8.25 years.  Age range of patients in the 
study was one to 56 years of age.  PE exacerbation samples were defined as those that were 
collected while a patient was admitted to the hospital, determined by location. 
 At least two respiratory specimens were collected on 23 of the 75 patients.  As a result, 
101 CF respiratory samples were tested throughout the duration of the study period.  Refer to 
Figure 2 for characteristics of the 101 patient samples analyzed. 
SAG.  Thirteen of the 75 patients were culture-positive for SAG.  Three patients had 
more than one specimen submitted during the study period; therefore, a total of 16 samples were 
analyzed.  Refer to Table 13 for a summary of SAG isolates detected in culture. The prevalence 
of SAG in the CF population during the study time frame was 17.33%.  This was calculated 
based on the total number of non-repeated patients culture positive for SAG (n=13) divided by 
the total number of CF patients included in the study (n=75) multiplied by 100.  Approximately 
54% of SAG recovered were from CF patients experiencing PE.   Coinfection with P. 
aeruginosa was also recorded. 
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Figure 2. CF Respiratory Sample Characteristics 
Table 13. SAG Isolates Cultivated on Study Media  
 
Sample ID Age Sample 
Tested 
Episode Coinfection with 
P. aeruginosa? 
S. anginosus 
20 A Sp Ex Yes 
35 A Sp Ex Yes 
38 A Sp S Yes 
49 A Sp Ex Yes 
S. constellatus 
8b P Sp Ex No 
30 P Es S No 
41 P Es S Yes 
51 P Sp S No 
52 P Es S No 
52b P Es S Yes 
56 A Sp Ex No 
S. intermedius 
36 P Sp Ex No 
38 A Sp S Yes 
42 P Sp S Yes 
52 P Es S No 
74b A Sp Ex Yes 
 
A=adult, P=Pediatric, Sp=Sputum, Es=Eswab, S=surveillance, Ex=Exacerbation 
 
Samples n=101 
 (49 Adults, 52 Peds) 
Sputum  
(n=62) 
Surveillance 
(n=32) 
Adults  
(n=21) 
Pediatrics  
(n=11) 
Exacerbations 
(n=30) 
Adults  
(n=23) 
Pediatrics  
(n=7) 
Eswab 
 (n=39) 
Surveillance 
(n=38) 
Adults 
(n=4) 
Pediatrics 
(n=34) 
Exacerbations 
(n=1) 
Adults 
(n=1) 
Pediatrics 
(n=0) 
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 Four S. anginosus isolates were identified from four different adult patients.  Three of 
these adult patients were experiencing a PE.  Only one S. anginosus was isolated in a 
surveillance culture.  All four patients were co-colonized with P. aeruginosa.  Some research 
groups have stated that SAG can possibly upregulate the virulence factors of classic CF 
pathogens. 
 S. constellatus was recovered in culture from six different patients.  One patient, with two 
data points during the study period, was repeatedly culture positive for S. constellatus. Five of 
the patients were pediatrics, and of those, four were surveillance cultures.  Only two of the 
pediatric patients who were culture positive for S. constellatus were co-infected with P. 
aeruginosa.  S. constellatus was isolated from only two samples collected during PE: one from a 
pediatric patient, and one from an adult patient.  Five of the six patients culture positive for S. 
constellatus were part of the pediatric population.  Unlike S. anginosus, this member of the SAG 
was predominantly found in those less than 18 years of age during a period of routine 
surveillance. 
 S. intermedius was isolated from five different CF patients during the study time frame.  
Three of those were pediatric patients; two during a time of surveillance and one experiencing a 
PE.  S. intermedius was isolated from two adult patients, both via surveillance cultures.  Two of 
the adult patients and one of the pediatric patients were co-colonized with P. aeruginosa.   
 In two patients, two members of the SAG were isolated in culture.  One was an adult 
patient, whose surveillance culture was positive for S. anginosus and S. intermedius.  The other, 
a pediatric patient, was co-colonized with S. constellatus and S. intermedius.   
 Anaerobes.  Brucella, PEA, and LKV/BBE agars were used to determine the prevalence 
of strict anaerobes in the CF population at VCUMC. Thirty-one of the 75 patients included in the 
 72 
 
study were culture positive for anaerobes in greater than or equal to quantities than the classic CF 
pathogens and/or normal respiratory flora.  This was determined by comparing growth on the 
anaerobic plates to growth on the BA at 35°C in ambient air.   Therefore, the prevalence of 
anaerobes in the CF population at VCUMC during the study time frame was 41.33%.   
Thirty-three of the 101 samples tested were positive for anaerobes in greater than or equal 
to quantities than the principle CF pathogens and/or normal respiratory flora. Twenty-eight of the 
75 patients (30 total CF respiratory specimens tested), were culture positive for Veillonella 
species (Table 14).  Of these 28 patients, 18 were pediatrics and 10 were adults.  In both age 
groups, the majority of anaerobes were recovered during periods of surveillance and only eight 
were coinfected with P. aeruginosa.  The remaining anaerobic species cultivated were  
Lachnoanaerobium umeaense, Lanchnoanaeroboculum ovale, Prevotella pallens, Prevotella 
melaninogenica, and Fusobacterium naviforme, which were all isolated from pediatric 
surveillance cultures.  One sample from one patient grew both L. umeaense and P. pallens.  The 
CF patient respiratory sample that grew F. naviforme was coinfected with P. aerugonisa.   
Colistin-Resistant NF GNR.  Ten of the 75 patients (15 total specimens) were culture 
positive for colistin-resistant NF GNRs recovered on both study media and in routine culture 
(Table 15).  Only four colistin-resistant NF GNRs were isolated.  Moreover, repeated samples on 
the same patients did not reveal new organisms.  However, three unique colistin-resistant NF 
GNRs were in four specimens using study media alone:  Sphinogomonas paucimobilis and  
Chryseobacterium gleum recovered from one patient (two separate samples), and A. 
xylosoxidans recovered from two separate patients (Table 16).  Therefore, the prevalence of  
colistin-resistant NF GNRs only on study media is 4%.  When both emerging and classic CF 
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Table 14. Veillonella species Cultivated on Study Media   
 
Sample ID Age Sample 
Tested 
Episode Coinfection with  
P. aeruginosa? 
V. aytpica 
1 A Sp S Yes 
1b A Sp Ex Yes 
9 P Sp S No 
10 A Sp Ex Yes 
14 P Es S No 
14b P Es S No 
18 A Sp Ex No 
24 P Es S No 
25 A Sp S Yes 
38 A Sp S Yes 
39 P Es S No 
44 A Es S No 
45 P Sp S No 
46 A Sp S Yes 
59 P Sp S No 
60 P Es S No 
64 P Es S No 
V. parvula 
12 P Es S No 
28 P Es S No 
49 A Sp Ex Yes 
61 P Es S No 
 
V. dispar 
7b P Es S No 
31b P Es S No 
36 P Sp Ex No 
66 A Sp S Yes 
68b P Sp Ex No 
70 P Es S No 
72 P Es S No 
74 A  Sp S Yes 
V. rogosae 
52 P Es S No 
 
A=adult, P=Pediatric, Sp=Sputum, Es=Eswab, S=surveillance, Ex=Exacerbation 
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Table 15. Colistin-Resistant NF GNR Cultivated on Routine and Study Media 
 
Sample ID Age Sample Type Episode Organism ID 
4 A Sp Ex B. cenocepacia 
4b A Sp Ex B. cenocepacia 
4c A Sp Ex B. cenocepacia 
5b A Sp Ex A. xylosoxidans 
P. aeruginosa 
16 A Sp Ex A. xylosoxidans 
16b A Sp S A. xylosoxidans 
26 P Es S S. maltophilia 
33 A Sp Ex A. xylosoxidans 
40 A Sp S A. xylosoxidans 
41 P Es S S. maltophilia 
56 A Sp Ex B. cenocepacia 
56b A Sp Ex B. cenocepacia 
74 A Sp S A. xylosoxidans 
74b A Sp Ex A. xylosoxidans 
75 A Sp Ex B. cenocepacia 
 
A=adult, P=Pediatric, Sp=Sputum, Es=Eswab, S=surveillance, Ex=Exacerbation 
 
Table 16. Colistin-Resistant NF GNR Cultivated Only on Study Media  
 
Sample ID Age Sample Type Episode Organism ID 
14 P Es S S. paucimobilis 
14b P Es S C. gleum 
18 A Sp Ex A. xylosoxidans 
38 A Sp S A. xylosoxidans 
 
A=adult, P=Pediatric, Sp=Sputum, Es=Eswab, S=surveillance, Ex=Exacerbation 
 
pathogens are combined, the prevalence of colistin-resistant NF GNRs in the population at 
VCUMC over the study period is 17.33%.  Colistin-resistant A. xyolsoxidans was isolated from 
seven of 13 patients, B. cenocepacia in three of 13 patients, and S. maltophilia in two of 13 
patients.   Providencia rettgeri and Serratia marcescens, members of the Enterobacteriaceae, 
were recovered from two separate patients.  Both isolates are colistin-resistant; however, since 
they are not considered NF GNRs, they were not included in the calculation for prevalence.  It  
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was noted that P. rettgeri was found in greater quantities than classic CF pathogens and normal 
respiratory flora. 
Specific Aim 3 
 
 Specific Aim 3 was accomplished by prospectively evaluating the current CF culture 
procedure routinely performed in the clinical microbiology laboratory at VCUMC with the CF 
research protocol.  Traditional CF cultures were read and reported by clinical laboratory 
scientists in the clinical microbiology laboratory at VCUMC.  These were compared with results 
obtained from the study protocol for consistency in reporting of pathogens.    
 SAG.  The presence of SAG was not reported in any of the routine CF respiratory culture 
results.  Members of the SAG are not specifically sought, and, the current procedure does not 
include a selective media for recovery of this group of organisms.   
 Anaerobes.  The routine CF respiratory culture protocol does not include media or 
incubation conditions to cultivate and isolate anaerobic bacteria from this population.  Therefore, 
all anaerobes reported were only from the research protocol. 
 Colistin-resistant NF GNR.  Four specimens from three different patients yielded 
colistin-resistant NF GNRs when cultivated and isolated on the study media.  These consisted of 
the following genus and species:  A. xylosoxidans, S. paucimobilis, and C. gleum (Table 16).   
Two isolates of A. xylosoxidans were recovered from adults; whereas, S. paucimobilis and C. 
gleum were recovered from one pediatric CF patient.   
Additional findings.  Seven respiratory samples from seven different CF patients grew 
fungus only on the study media, specifically TSA with 15 mg/L of colistin and 16 mg/L of 
vancomycin (Table 17).  The majority of these samples were collected from the pediatric CF 
population.  In addition, most of these samples were collected during periods of surveillance.  
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Table 17. Culture Discrepancies Between Routine and Research CF Protocols 
 
Sample ID Age Sample Type Episode Discrepancy  
*Isolated in Research 
Protocol Only 
3 P Sp S Fungus 
10 A Sp Ex Fungus 
18 A Sp Ex A. xylosoxidans 
38 A Sp S A. xylosoxidans 
42 P Sp S Fungus 
51 P Sp S Fungus 
59 P Sp S Fungus 
68 P Sp Ex Fungus 
71 A Es Ex Fungus 
14 P Es S S. paucimobilis 
14b P Es S C. gleum 
 
A=adult, P=Pediatric, Sp=Sputum, Es=Eswab, S=surveillance, Ex=Exacerbation 
 
Summary 
 This chapter discussed the results of Specific Aims 1 through 3.  Specific Aim 1 
highlighted the development, optimization, validation, and implementation of the culture-
dependent media used to target emerging pathogens in the CF population at VCUMC.  Recovery, 
media verification, and optimal incubation conditions were determined for McKay agar, MAC 
with 15 mg/L of colistin, and TSA with 15 mg/L of colistin and 16 mg/L of vancomycin.  
McKay agar performed best under anaerobic conditions, and both MAC with colistin and TSA 
with colistin and vancomycin performed well in both 35°C ambient air and 35°C CO2.  The 
prevalences of SAG, anaerobes, and colistin-resistant NF GNRs for the CF population at 
VCUMC over the study period were calculated as 17.33%, 41.33%, and 4%, respectively.  
Finally, discrepancies between the routine and research protocol culture, consisting of additional 
colistin-resistant NF GNRS recovered in the research protocol only as well as the unexpected 
cultivation of fungus on TSA containing colistin and vancomycin were described.   
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Chapter 5:  Discussion 
 
Introduction 
 A summary of the research is presented in this chapter, and findings of the study are 
discussed and interpreted.  The significance of these results, in the context of emerging CF 
pathogens is examined and compared to the literature.  Implications of the results to current 
practice and recommendations for CF culture protocols is presented.  Limitations and future 
research directions are discussed.   
 Molecular profiling studies have revealed the vast number and complexity of microbial 
communities in the CF lung. Based on these studies, several emerging pathogens, hypothesized 
to play a direct or indirect role in pulmonary exacerbations, have been widely recognized and 
discussed (Sibley et al., 2011; Zhao et al., 2012).  Currently, it is not feasible to perform 
molecular profile analysis on CF surveillance cultures.  In fact, molecular profiling studies are 
only recommended when epidemiologically indicated (CF Foundation, www.cff.org).  Therefore, 
in order to determine the role of these potential emerging pathogens in CF lung disease, and 
potentially add to the reporting scheme in the clinical rather than research setting, culture-
dependent microbiology screening protocols were developed. Several emerging pathogens, 
thought to play a direct or indirect role in PEs, were specifically targeted in culture.  In order to 
recover these targeted CF pathogens from respiratory samples, selective media was developed 
and/or purchased for use in the study protocol. 
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SAG 
 McKay agar was able to cultivate and isolate SAG in CF respiratory cultures.  Although 
anaerobic incubation conditions were assessed in previous studies (Sibley et al., 2008; Sibley et. 
al, 2011), results were not discussed.  Therefore, in this study, performance of McKay agar was 
assessed at three different atmospheric conditions:  35°C, 35°C CO2, and 35°C in anaerobic 
environment.  Initial limit of detection studies, utilizing three ATCC strains of SAG, revealed 
that recovery was increased when McKay agar was incubated at 35°C under anaerobic 
conditions.  In addition, appearance of the colonies were larger in size on McKay agar under 
anaerobic conditions.  It was noted that McKay agar did not support the growth of S. intermedius 
(ATCC 27335) or S. constellatus (ATCC 27823) when incubated in ambient air at 35°C.  It is 
important to note that SAG was not observed on BA included in the study protocol (35°C with 
CO2) due to possible overgrowth by normal respiratory flora and CF pathogens, such as S. aureus 
and mucoid P. aeruginosa.   
 Members of the SAG have been labeled as a CF respiratory pathogens capable of playing 
a role in acute PE by several groups (Sibley et al, 2008; Parkins et al, 2008; Grinwis et al., 2010; 
Sibley et al., 2010; Sibley et al., 2011;. Filkins et al., 2012; Asam and Spellerberg, 2014; 
Navratilova et al., 2016).  The reported prevalence of SAG in the CF population at VCUMC 
during the study period was 17.33%.  Sibley et al. (2008) presented multiple case reports in 
which SAG was the numerically dominant pathogen during periods of PE.  When SAG was 
specifically targeted for treatment, clinical response was observed.  In this study, 53.8% of SAG 
recovered in culture were from CF patients experiencing PE.  Recurrent episodes of PE in CF 
patients are associated with long term decline in lung function and shortened survival.  Selecting 
for SAG in culture with McKay agar would allow cultivation and identification of this emerging 
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pathogen and provide clinicians with an additional treatment target when managing CF patients 
experiencing PE. 
 In the current study, percent species breakdown of SAG in the CF population at VCUMC 
is as follows:  S. anginosus (25%), S. intermedius (31%), and S. constellatus (44%). These 
results are similar to those reported by Sibley et al. (2010).  An overall SAG prevalence of 40.6% 
in 108 CF patients over a six-month period was reported by incorporating McKay agar in the 
culture protocol.  These isolates were further classified by species.  S. anginosus constituted 
40.7% of the recovered SAG isolates, S. intermedius comprised 34.3%, and S. constellatus 
accounted for 25%.    These results indicate that SAG is present and persistent in CF patients.   
 Similar to the findings in this study, Navratilova et al. (2016) reported a SAG prevalence 
of 17.6% in the CF population studied.  Recognizing the potential of SAG to cause PEs, this 
emerging pathogen was sought in patients with other lung disorders, such as chronic obstructive 
pulmonary disease (COPD).  SAG prevalence in this population was 10.3%.  Acknowledging the 
role of SAG in PE as well as modifying culture protocols to detect this group in CF pulmonary 
samples is necessary to provide optimal patient care.   
Anaerobes 
Three different types of anaerobic media, Brucella, PEA, and BBE/LKV were 
incorporated in the study protocol.  This media combination is expensive, and after conducting 
the study, it was concluded that only one anaerobic media type, Brucella, was actually needed.  
Anaerobes were only identified if they were in greater than or equal quantities than the classic 
CF pathogens and/or normal flora.  This was easily assessed on Brucella agar alone, which could 
reduce future costs and labor intensiveness of reading culture plates.   
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Based on the results of molecular profiling studies in research settings, there has been a 
renewed interest in anaerobes and the role they play in CF lung disease (Sibley et al., 2012, Zhao 
et al., 2012; Sherrard et al., 2016; Tunney et al., 2008; Pustelny et al., 2015).The prevalence of 
anaerobes in the CF population at VCUMC was 41.33%.  Interestingly, Veillonella spp. was 
isolated from 28 patients.  Only six of these 28 patients were experiencing a PE.   Only seven of 
the patients from which Veillonella species was recovered were coinfected with P. aeruginosa.  
A recent study reported on the interaction of Veillonella parvula with P. aeruginosa in a 
murine tumor model (Pustelny et al., 2015).  Significantly higher cell numbers of P. aeruginosa 
were recovered from tumor tissue when the mice were coinfected with both organisms.  In vitro 
studies suggested that V. parvula may promote the development of robust P. aeruginosa 
aggregates and mature biofilm structures.  Again, this supports the claim that organisms 
previously considered to be normal respiratory flora in CF patients, can potentially upregulate 
the virulence factors of the principle pathogen, P. aeruginosa.  Further studies are required to 
determine if anaerobes contribute to the microbial diversity of the CF lung, corresponding with 
periods of clinical stability; or, if in fact, they, too, could be potentially used as a microbiologic 
marker of PE. 
CF pulmonary infections are polymicrobial; and it is possible that anaerobic bacteria, not 
detected by routine aerobic culture, reside within infected airway mucous.  Tunney et al. (2008) 
conducted a study to determine whether anaerobic bacteria was present in the sputum of patients 
with CF.  Anaerobes in quantities greater than 10
4
 were identified and reported.  The prevalence 
of obligate anaerobes in the 50 CF patients studied was 66%.  A total of 66 samples were 
collected from these 50 patients.  Sixty-three percent of those revealed anaerobes in quantities 
greater than or equal to 10
4.  
Anaerobes detected were similar to those involved in anaerobic 
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pulmonary infections such as nosocomial pneumonia, lung abscesses, and empyema, where the 
presence of aerobic and anaerobic bacteria were considered to be a significant finding. Twenty-
seven samples were positive for both P. aeruginosa and anaerobes.  Eleven of the samples 
culture negative for P. aeruginosa were positive for anaerobes.  These data suggest that 
anaerobes may cause early infection, and over time, produce a hospitable environment for 
subsequent infection with P. aeruginosa.       
In the current study, anaerobes were identified if present in greater than or equal to 
quantities than the principal CF pathogens.  The population prevalence of anaerobes was 
41.33%.  Thirty-three of the 101 (32.67%) samples collected from 75 CF patients were positive 
for anaerobes during the study period.  Ten of the 33 samples were culture positive for both P. 
aeruginosa and anaerobes (30.33%) and 23 (69.69%) were culture negative for P.aeruginosa and 
positive for anaerobes.  High quantities of anaerobes may be unique to CF patients and play a 
possible role in lung disease. 
Field et al. (2010) detected Prevotella spp. in combination with SAG from CF patients at 
the onset of PE.  Prevotella spp. were isolated in two patients in this study, resulting in a 
prevalence of 6.45%.  Both were pediatric patients during a period of routine surveillance and 
cultures were negative for P. aeruginosa and SAG.  A pediatric respiratory sample collected 
during PE in this study was culture positive for F. naviforme, P. aeruginosa, and S. constellatus.  
These findings further support the claim that interspecies interactions among emerging 
pathogens such as anaerobes and SAG with classic pathogens, such as P. aeruginosa, may result 
in periods of clinical instability or PE.   
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Colistin-Resistant NF GNRs  
Isolation and identification of all colistin-resistant NF GNRs, regardless of quantity, 
should be identified by methods such as MALDI-TOF or DNA sequencing.  Colistin is used as a 
last line of defense to treat colistin-resistant P. aeruginosa, and any NF GNR exhibiting 
resistance in culture should be reported to clinicians (Kiska and Riddell, 2012).  The prevalence 
of colistin-resistant NF GNRs found only on study media was 4%, and the prevalence of those 
found in both the routine and research culture protocols was 17.33%. There was one colistin-
resistant NF GNR isolated that was unable to grow on MAC, C. gleum.  However, this organism 
was cultivated and isolated on TSA with colistin and vancomycin.  In two instances, the study 
media isolated two colistin-resistant strains of A. xylosoxidans from two separate patients that 
was not reported in routine culture.  The selective nature of the study media prevented the mixed 
respiratory flora and classic CF pathogens from overgrowing and obscuring the growth of A. 
xylosoxidans.  Both samples were obtained from adults experiencing a PE, where A. 
xylosoxidans would be targeted for antimicrobial therapy.  Two colistin-resitant NF GNRs, S. 
paucimobilis and C. gleum, were recovered from one pediatric patient separately at two different 
time points during periods of surveillance.  These organisms are opportunistic and ubiquitous in 
the environment.  Their presence in culture may indicate improper maintenance or cleaning of 
respiratory equipment.  
I. limosus, an emerging CF pathogen, is a colistin-resistant NF GNR unable to grow on 
MAC.  The appearance of this organism on BA and CHOC agars resemble the appearance of 
mucoid P. aeruginosa.  This organism was specifically sought in culture; however, it was not 
isolated from any patient during the study time frame.  
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Fungus 
  One unexpected finding was the cultivation of yeast and fungi on the colistin-containing 
media, particularly TSA.  Incorporation of colistin and vancomycin suppressed the growth of 
Gram-positive organisms and colistin-sensitive bacteria allowing the slower growing yeast and 
fungus to grow without competition. This media recovered all fungi reported in the routine CF 
culture protocol.  In addition, fungus was present in seven patient samples on study media only, 
three of which were collected during periods of PE.  Therapeutic regimens differ for bacteria and 
fungus.  The presence of fungus in CF respiratory cultures should be reported and considered by 
physicians when treating patients, as it offers an additional therapeutic target.  Aspergillus 
fumigatus can cause allergic bronchopulmonary aspergillosus in up to 15% of CF patients.  This 
complication can cause repeated acute exacerbations leading to an accelerated decline in lung 
function. 
A. fumigatus and P. aeruginosa both form biofilms in vivo and in vitro which provide 
organisms with protection from host defenses as well as tolerance to some drugs.  P. aeruginosa 
secretes molecules such as homoserine lactones, pyocyanin, and fluorescent green pigments 
which have all been studied for their antifungal activities (Ferreira et al., 2015).  Approximately 
80% of adult CF patients are infected with P. aeruginosa.  When this principal pathogen is 
present with A. fumigatus in culture, it may inhibit the growth of the fungus preventing 
cultivation and identification of this CF pathogen.  Granillo et al. (2015) reported the same type 
of phenomenon with S. aureus, a classic CF pathogen, and A. fumigatus.  S. aureus inhibited the 
development of the biofilm formed by A. fumigatus in vitro.  This pathogen could also be 
responsible for inhibiting the growth of fungus in routine CF culture.  Failure to identify and 
report fungus in CF respiratory cultures can impact patient outcomes as antifungals instead of 
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antimicrobials are implicated for treatment.  Further prospective studies are needed to determine 
the ability of TSA with colistin and vancomycin to reliably recover fungus from CF patient 
respiratory samples.  
Limitations 
 Ideally, in order to get a representative sample of the lower airways, sputum should be 
obtained from each patient.  In the event that a patient cannot produce sputum, which is common 
in the pediatric CF population, an Eswab is collected for analysis.  Excluding samples collected 
with Eswabs would decrease the number of participants and inadequately represent the 
population of CF patients at VCUMC.  Emerging pathogens were frequently recovered from CF 
respiratory samples collected by Eswabs in this study. 
 When anaerobes are suspected in culture, transport, receipt, and plating should occur as 
soon as possible to ensure optimal recovery.  In this study, either sputum or Eswabs were 
collected and transported to the lab.  According to the manufacturer, Eswabs maintain the 
viability of aerobic and anaerobic bacteria for up to 72 hours.  When sputa is collected, it is not 
feasible for the specimen to be collected and plated within an hour of collection; therefore, this 
may impact the recovery of anaerobes.  All CF respiratory samples included in this study were 
plated to the study media within 48 hours of receipt in the clinical microbiology laboratory.  
 Another noted limitation is sample size.  This study determined the prevalence of 
emerging pathogens in 75 CF patients, from which a total of 101 respiratory samples were 
collected.  Multiple data points were obtained on 23 of the 75 patients.  Increasing the sample 
size and obtaining multiple culture data points, ideally four to five per patient, would determine 
if the presence of these emerging pathogens in culture represent transient versus chronic 
colonization.  In addition, multiple data points would further describe the association of these 
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pathogens with periods of PE and allow more unique analysis of subgroups.  However, the 
sample size of 75 in this study is comparable to other studies in the literature.  In this study, 
periods of PE were defined by hospitalizations.  A clear-cut definition of PE does not exist; 
therefore, periods of PE may be defined in different ways by other researchers.  
 The prevalence of emerging pathogens in the CF population at VCUMC was calculated.  
Prevalence of emerging pathogens may differ among CF clinics by patient population and even 
geographic distribution, which impacts the generalizability of these findings.  Results are specific 
to the population studied; however, the method to determine prevalence of emerging pathogens 
can be easily reproduced in other settings.   
Future Studies 
 The results of this study confirmed that emerging pathogens cited in the literature are 
present in the respiratory samples of CF patients at VCUMC.  A longitudinal study, conducted in 
the same fashion, would be helpful to further describe the role of SAG in CF respiratory cultures.  
In addition, in order to determine the role emerging pathogens play in PE and if culture can serve 
as a microbiologic indicator of lung function decline, clinical data should be correlated with 
culture results.  Results of pulmonary lung function tests (FEV), body mass index (BMI), and 
antimicrobial therapeutic regimens have been used in previous studies. Collaboration with CF 
pulmonologists would assist in bridging this gap in order to gain a better understanding of the 
role of emerging pathogens in this population.  A prospective study, evaluating the use of TSA 
with colistin and vancomycin to recover fungus in CF respiratory cultures is warranted.  Study 
protocol results could be compared for consistency with fungus culture results.  Another type of 
selective media, NAS agar, has been used in recent studies to recover SAG from clinical samples 
cultures.  Raclavsky et al. (2016) compared McKay agar to NAS agar using 123 patient samples.  
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Overall, NAS was able to recover greater numbers of SAG.  However, it was noted that a 
fraction of strains grew better on McKay agar.  A future study could assist in comparing these 
two selective media for the recovery of SAG in CF respiratory samples.   
Conclusion 
Molecular profiling studies have identified potential emerging pathogens, such as SAG, 
anaerobes, and colistin-resistant NF GNRs, and suggest their involvement in the progression of 
CF lung disease.  In the clinical setting, these methods are not routinely used or recommended to 
monitor CF patients.  Therefore, culture-dependent screening techniques were developed, 
optimized, and implemented in this study to determine the prevalence of targeted emerging 
pathogens in the CF population at VCUMC.  
 Results revealed that emerging pathogens are present in CF respiratory samples, many of 
which were collected from patients during periods of clinical instability.  Expanding the list of 
CF pathogens sought in culture could provide additional therapeutic targets for physicians.  
Initiating treatment earlier, specifically directed against emerging pathogens thought to play a 
role in PE, could improve patient outcomes by decreasing hospitalizations and associated costs 
as well providing more targeted versus broad spectrum antibiotic therapy.   
  The dynamic microbiome within the CF airway, consisting of classic CF pathogens as 
well as emerging pathogens, must be considered to effectively manage and treat patients. 
Therefore, the routine culture protocol needs to be revised to select for emerging CF pathogens 
thought to play a role in PE and lung function decline.  In order for definitive conclusions to be 
made, the presence of emerging pathogens in CF cultures coupled with clinical data should be 
evaluated to further define their role in PE and lung function decline. 
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Appendix A 
Routine CF Culture Protocol 
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I. PRINCIPLE 
The culture of respiratory secretions from cystic fibrosis (CF) patients presents unique 
challenges for the microbiologist that requires patience and determination.  The most 
significant organism associated with CF is a highly mucoid, nonpigmented strain of 
Pseudomonas aeruginosa.  The nature alone of this mucoid P. aeruginosa necessitates 
the use of a vigorous and selective protocol to ensure isolation of the other major CF 
pathogens.  Refer to section VII., Procedure Notes for more detailed information on 
cystic fibrosis. 
 
II. CULTURE MEDIA 
Media Incubation 
35
o
C-CO2 35
o
C-
nonCO2 
LOI 
BAP   4 days 
MAC    
CHOC    
CNA    
BCSA    
MS    
LOI=Length of Incubation.    
 
III. POTENTIAL PATHOGENS/NORMAL FLORA 
 A. Potential Pathogens 
  1. Mucoid Pseudomonas aeruginosa 
2. Non-mucoid Pseudomona aeruginosa 
3. Staphylococcus aureus (including small colony variant) 
4. Haemophilus influenzae 
5. Burkholderia cepacia 
6. Fungi – mould 
7. Beta-hemolytic Streptococcus 
8. Stenotrophomonas maltophilia 
9. Streptococcus pneumoniae* 
10. Other non-fermenting gram-negative bacilli* 
  11. Other Haemophilus species* 
  12. Enterobacteriaceae** 
13. Moraxella catarrhalis** 
  14. Neisseria meningitidis** 
15. Yeast** 
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*Quantity = moderate-many; **Quantity = predominating 
 
B. Normal Flora 
  1. Alpha-hemolytic (viridans) Streptococcus 
  2. Non-hemolytic Streptococcus 
  3. Enterococcus species 
  4.  Staphylococcus species, coagulase-negative 
  5. Micrococcus species 
  6. Corynebacterium species and other gram-positive rods  
  7. Neisseria species (saprophytic) 
8. Streptococcus pneumoniae* 
9. Other non-fermenting gram-negative bacilli* 
  10. Other Haemophilus species* 
  11. Enterobacteriaceae** 
12. Moraxella catarrhalis** 
  13. Neisseria meningitidis** 
14. Yeast** 
  *Quantity = few; **Quantity = not predominating over normal flora 
IV. SAFETY:  If any organism resembling Neisseria meningitidis or Haemophilus spp. 
(grey, translucent colony morphology on CHOC agar) is isolated, or if gram-negative 
diplococci are predominating in the direct Gram stain of the culture: 
A. Take all plates to a BSL-2 hood. 
 
B. Perform all work, including MALDI setup, under the hood until N. meningitidis is 
ruled out. 
 
C. Shrink-seal all plates. 
 
V. CULTURE EXAMINATION AND INTERPRETATION 
A. Culture Exam 
1. At 24 hours: 
a. Examine all plates for normal respiratory flora and the appearance 
of any significant CF pathogens (see table, page 3-4). 
b. If significant pathogens are present, see interpretation section 
below for extent of workup. 
c. Reincubate all plates. 
d. Issue a preliminary report as described in section VII.B.1. 
  2. At 48 hours and 72 hours: 
   a. Re-examine all plates as above (section V.A.1.a-b). 
   b. Reincubate all plates. 
c. Issue preliminary reports as described in section VI.B.2-3. 
  3. At 96 hours (4 days): 
   a. Re-examine all plates as above (section V.A.1.a-b). 
b. Issue preliminary reports as described in section VII.B.4. 
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c. If no apparent CF pathogens have appeared, issue a final report as 
described in section VII.C. 
 
B. Interpretation and Extent of Workup 
 1. Special considerations for CF cultures: 
a. Wait until there is sufficient growth before attempting any 
subcultures; this can take 3-4 days. 
b. Subculture all isolates prior to identification and susceptibility 
testing and incubate until growth is sufficient to ensure a pure 
culture. 
c. Hold all original media and all plates that have been subcultured 
and worked from in the plate reader’s “workup stack” until the 
culture is complete. 
d. Review the patient’s previous cultures in Micro Inquiry. CF 
patients usually grow the same organisms for extended periods of 
time. The susceptibility patterns often remain constant, but can 
change over time. 
2. Examine all media for appearance of mucoid Pseudomonas aeruginosa: 
 a. Slow grower (48 to 72 hours) on BAP, CHOC, MAC.  
 b. Non-pigmented, non-lactose fermenter. 
 c. Starts out wet; gradually turns into sticky gum-like slime. 
 
3. Examine MS for S. aureus:  Most strains of S. aureus grow on MS and 
produce yellow zones around the colonies as a result of mannitol 
fermentation. 
a. Occasionally, some strains produce white colonies on MS. 
b. If both parent and small colony variant S. aureus are present, only 
perform ID and sensis on parent colony. 
4. Examine BCSA for Burkholderia cepacia complex:  
a. Usually slow grower (3 to 4 days).  
b. Colonial Morphology:  variable = small to large, dry to moist. 
  c. Colonial Appearance:  
i. Colonies that absorb the crystal violet dye = purple to 
purple-gray. 
ii. Acid production from carbohydrate oxidation = yellow 
zone in the medium surrounding the colony. 
iii. Peptone utilization = pink zone in the medium surrounding 
the colony. 
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d. Key biochemical reactions for B. cepacia:  Oxidase = positive, but 
may appear negative initially. 
e. This media is highly selective against gram-negative rods, but 
some breakthrough growth can occur.  Examples are: 
i. Burkholderia gladioli, which produces a natural yellow, 
pigment, but is oxidase-negative. 
ii. Stenotrophomonas maltophilia. 
iii. Achromobacter xylosoxidans. 
5. If B. cepacia, Burkholderia gladioli, or Ralstonia pickettii cannot be ruled 
out, check Micro Inquiry to determine if the patient has grown the 
organism previously. 
a. If no previous cultures have grown these organisms, send the 
isolate to the Burkholderia cepacia Research Laboratory and 
Repository for confirmation.  
i. Refer to page 6 for instructions. 
ii. Reporting:  see section VI.B.5, page 4. 
b. If the organism has been identified in previous cultures, report as 
described in section VI., page 4.  
6. Use the following table as a guide to differentiate normal respiratory flora 
from potential CF pathogens and to determine extent of workup: 
Organism Quantity  Workup
  
Alpha-hemolytic (viridans) 
Streptococcus 
Any  None = Normal 
respiratory flora 
Non-hemolytic 
Streptococcus 
Any  None = Normal 
respiratory flora 
Enterococcus species Any  None = Normal 
respiratory flora 
Staphylococcus, coagulase-
negative 
Any  None = Normal 
respiratory flora 
Micrococcus species Any  None = Normal 
respiratory flora 
Corynebacterium species 
and other gram-positive 
rods 
Any  None = Normal 
respiratory flora 
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Neisseria species 
(saprophytic) 
Any  None = Normal 
respiratory flora 
Moraxella (Branhamella) 
catarrhalis 
Predominant ID and -lactamase  
Neisseria meningitidis Predominant ID  
Enterobacteriaceae Predominant ID and AST 
 
Organism Quantity  Workup
  
Yeast Predominant “Feet” 1 = C. albicans 
No “feet” = send to 
Mycology 
Streptococcus pneumoniae Moderate ID & AST 
Haemophilus species Moderate ID, -lactamase;  
AST if H. influenzae 
Burkholderia gladioli Any  ID and AST 
Ralstonia pickettii Any  ID and AST 
Fungi  mould Any  Send to Mycology  
(Mycology will 
update report) 
Stenotrophomonas 
maltophilia 
Any ID and AST 
Other non-lactose-
fermenting, gram-negative 
bacilli 
Moderate ID and AST 
Beta-hemolytic 
Streptococcus (large 
colony) 
Any  ID 
Staphylococcus aureus Any  ID and AST 
Mucoid Pseudomonas 
aeruginosa 
Any  ID and AST 
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non-Mucoid Pseudomonas 
aeruginosa 
Any  ID and AST 
Burkholderia cepacia Any  ID and AST 
1”Feet” = Pseudoprojections from colony on BAP or CHOC within 48 
hours. 
 
VI. IDENTIFICATION AND SUSCEPTIBILITIES 
A. Refer to Manual 105, as needed for identification procedures. 
 
B. Refer to Manual 106, as needed for susceptibility testing. 
 
VII. REPORTING 
A. Report Panic Values as indicated in procedure 100.7.2.   
 
B. Preliminary Reports 
  1. At 24 hours, report: 
   a. CI = “Continuing Incubation”.  
b. Do not report any growth of normal flora or potential pathogens at 
this point. 
2. At 48 hours, issue another report: 
a. If no apparent growth of CF pathogens at this time, quantitate the 
normal respiratory flora and report:  
i. negp = “_____ Mixed Respiratory Flora, Continuing 
Incubation.”    
ii. If CF pathogens are present, quantitate and report normal 
respiratory flora as above and report the pathogen(s).  
3. At 72 hours:  report any CF pathogens that appear and update the report as 
needed. 
4. At 96 hours:  report any CF pathogens that appear and update the report as 
needed. 
5. For first-time isolates of B. cepacia, B. gladioli, or Ralstonia pickettii 
report: 
a. Send Buce = “Presumptive _____________ Sent to CFF 
Burkholderia cepacia Research Laboratory and Repository for 
confirmation.”   
b. DO NOT FINALIZE THE CULTURE until confirmation is 
returned. 
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 c. Do not report susceptibility results until identification is received 
from Burkholderia cepacia Research Laboratory & Repository. 
 
C. Final Reports 
1. If no apparent CF pathogens have appeared after 96 hours (4 days), 
finalize the culture and report:  negf = “______ Mixed Respiratory Flora.”  
2. For positive cultures, finalize the culture when all identification and 
susceptibilities are completed. 
 
VIII. PROCEDURE NOTES 
A. Cystic Fibrosis (CF) is the most common lethal genetic disorder seen in 
Caucasians.  Progressive pulmonary disease, commonly associated with infections 
in conducting airways, is the principle cause of morbidity and mortality in CF.  
Another condition associated with CF is pancreatic insufficiency with 
malnutrition.  Both syndromes are the result of the production of extremely 
viscous secretions.  These secretions cause blockage of the pancreatic ducts 
resulting in an inability to secrete digestive enzymes and, more significantly, the 
development of chronic lung infections due to several types of organisms.  The 
most significant organism associated with CF is a highly mucoid, nonpigmented 
strain of Pseudomonas aeruginosa. During the past decade, another nonfermenter, 
Burkholderia cepacia, has also been recognized as a significant pathogen in these 
patients.  Two factors are extremely important when considering Burkholderia 
cepacia.  First, approximately 20% of patients who become infected will have a 
rapid decline in their pulmonary function, and death will occur in 1 to 6 months.  
Second, there is accumulating evidence that some clones of Burkholderia cepacia 
can be transmitted person-to-person.  These patients are often isolated from all 
other CF patients, making them social outcasts in the tightly-knit CF community. 
 
B. Burkholderia cepacia complex is a group of organisms that are genetically and 
sometimes biochemically distinct from each other.  Although nine genomovars 
are now recognized in the B. cepacia complex, over 85% of the isolates recovered 
from CF patients belong to either genomovar III (50%) or genomovar II (38%).  
Several genomovars have species names while others are still awaiting 
designation. 
 
IX. REFERENCES 
A. Murray, Patrick R., E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken.  2003.  
Manual of Clinical Microbiology, 8th Edition.  ASM Press, Washington, D.C.  
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systems for the identification of Burkholderia cepacia and other gram-negative 
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Microbiol. Apr:34(4):886-91. 
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SEND-OUT INSTRUCTIONS FOR Burkholderia spp. 
 
I. BACKGROUND 
The Burkholderia cepacia Research Laboratory and Repository was established in 1998 
and is funded by the CF Foundation.  The laboratory is located currently at the University 
of Michigan in Ann Arbor and is directed by Dr. John LiPuma.  The laboratory makes the 
following services available free of charge to all CF care centers: 
A. Confirmation of species identification – Putative Burkholderia spp. recovered 
from CF sputum undergo polyphasic analyses to confirm species identity.  The 
laboratory can rule out Burkholderia spp. among nonenteric, nonfermenting, 
gram-negative bacteria for which species identification is uncertain. 
B. Genomovar designation – Isolates confirmed as B. cepacia complex are analyzed 
to determine their species (genomovar) within the complex. 
C. Isolate genotyping (DNA fingerprinting) – Upon request the laboratory will 
provide typing by RAPD and/or PFGE to assess strain identity among isolates 
submitted.  This allows investigation of possible person-to-person transmission or 
nosocomial acquisition. 
D. Isolate respository – All isolates are catalogued and stored.  This provides an 
important resource for future epidemiologic studies. 
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II. PROTOCOL FOR SENDING ISOLATES 
A. Send any isolate identified as Burkholderia spp. or Ralstonia pickettii for the first 
time from any CF patient. 
B. Send only pure isolates from fresh overnight cultures on a TSA slant. 
C. Complete a PHYSICIAN AND PATIENT INFORMATION REFERRAL 
FORM for each isolate sent. 
1. Forms can be found in a labeled notebook (CF Send-Outs) located on 
Respiratory Bench. 
 2. See example form in front of notebook. 
3. Make a copy of each form and file in notebook behind the front tab – 
PENDING. 
 4. Send the original form with the isolate. 
D. Send copies of our ID and Susceptibility reports for each isolate. 
E. Isolates must be packed/shipped by a person in the laboratory certified to ship 
hazardous goods.  Multiple isolates can be shipped in the same box if necessary.  
F. Send by UPS 2nd Day Air and bill to recipient’s account No. WO4Y00.  Send to:  
Dr. John LiPuma     For more information: 
1150 W. Medical Center Drive   Tel:  734-936-9767  
8323 MSRB III, SPC 5646   FAX: 734-615-4770 
 Ann Arbor, MI  48109-5646 
H. When results are returned:  enter the results in a Final report for the isolate as 
follows:   
1. Buce Confirm = “_____   Confirmed by CFF Burkholderia cepacia 
Research Laboratory and Repository.” 
2. Attach report to referral form.  File in COMPLETE section of CF Send-
Outs notebook. 
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Appendix B 
Anaerobe Protocol 
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I. PRINCIPLE 
Wound colonization and/or infection is often polymicrobic, with both aerobes and 
anaerobes involved.  A hallmark of local infection within an abscess or deep wound is an 
accumulation of inflammatory cells.  Subsequent pus formation can be documented by 
the presence of PMNs in the gram-stained smear.  Therefore, the quality of a wound or 
tissue specimen can be assessed by Gram stain, which should be used to guide the extent 
of microbiology testing.  The presence of epithelial cells indicates contamination of the 
specimen with skin or mucous membrane microbiota and may compromise the 
significance of the culture results.   
 
Obviously, this procedure cannot possibly outline every possible scenario for wound or 
tissue culture examination and interpretation.  A Composite Q Score algorithm (pg 4) is 
used to help the technologist integrate all available data.  A certain amount of 
microbiological intuition is required to interpret each culture.  In an effort to offer the 
physician clinically relevant, accurate and cost-effective information, the technologist 
must integrate direct observations of bacterial growth (aerobic and anaerobic) with direct 
Gram stain, patient diagnosis, and specimen source.  This procedure also details reporting 
guidelines for the most common potential pathogens (pg 4-5), as well as cultures with 
mixed organisms.   
 
II. MATERIALS 
Media Incubation 
 35
o
C-CO2 35
o
C-
nonCO2 
ANA LOI 
CNA    3 days 
MAC     
TM*      
BA    5 days 
BR     
CHOC     
KV     
PEA     
*Add for genital and joint sources. 
 
III. POTENTIAL PATHOGENS AND NORMAL FLORA 
 A. Potential Pathogens 
1. Actinomyces spp. (must be incubated for 14 days in an anaerobic pouch in 
the anaerobic chamber)  
2. Anaerobes  
3. Bartonella spp. 
4. Beta-hemolytic streptococci* 
5. Coagulase-negative Staphylococci (needs to be evaluated in each 
circumstance) 
6. Eikenella spp. 
7. Enterococcus spp. 
8. Enteric gram-negative rods 
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9. Erysipelothrix spp. 
10. Fungus 
11. Haemophilus spp. 
12. Listeria spp. 
13. Mycobacterium spp. 
14. Neisseria gonorrhoeae 
15. Neisseria meningitidis 
16. Nocardia spp.   
17. Non-fermenting gram-negative rods including Pseudomonas 
aeruginosa** and Acinetobacter spp.   
18. Pasteurella spp.   
19. Staphylococcus aureus* 
20. Staphylococcus lugdunensis 
21. Streptococcus milleri group 
22. Streptococcus pneumoniae 
23. Yeast 
  NOTE: Always report organisms with an * regardless of Q score.  Always report 
organisms with a ** if predominating, regardless of Q score.   
 
 B. Potential Bioterrorism Pathogens 
  1. Francisella spp. 
  2. Yersenia pestis 
  3. Bacillus anthracis 
  4. Brucella spp. 
 
 C. Normal Flora 
1. Aerococcus spp. 
2. Corynebacterium spp. 
3. Lactobacillus spp. 
4. Micrococcus spp. 
5. Non-pathogenic Neisseria spp. 
6. Peptostreptococcus spp. 
7. Propionibacterium spp. 
4. Coagulase-negative Staphylococcus  
5. Viridans streptococci 
NOTE: Under some circumstances, depending on the Q score and the body site, 
these organisms may need to be worked up.   
 
IV. SPECIAL PRECAUTIONS AND SAFETY 
 A. Refer to procedure 114.8 for a list of select agents that require special handling.  
 
B. Day 2 culture examination 
1. If there is faint or newly appearing growth, move plates to biological 
safety cabinet, then perform a Gram stain (GS). 
  2. If GS reveals tiny amorphous or small gram-negative coccobacilli, 
proceed with all further workup under biosafety hood in AFB laboratory 
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until Brucella spp. and/or Francisella spp. are ruled out.  Refer to SOPs in 
Manual 114 (Bioterrorism). 
  3. If GS reveals beaded or faintly staining rods, seal plate and give to the 
Mycology/AFB laboratory until Mycobacterium spp. or Nocardia spp. are 
ruled out.   
 
C. If any organism resembling Neisseria meningitidis or Haemophilus spp. (grey, 
translucent colony morphology on CHOC agar) is isolated, or if gram-negative 
diplococci are predominating in the direct GS of the culture: 
1. Take all plates to a BSL-2 hood. 
2. Perform all work, including MALDI set-up, under the hood until N. 
meningitidis is ruled out.  
3. Shrink-seal all plates. 
 
V. CULTURE EXAMINATION AND INTEPRETATION 
 A. Culture Exam 
1. At 24 hours: 
  a. Examine aerobic plates for growth.  Do not examine anaerobe 
plates at this time. 
   b. If no growth, reincubate plates. 
 c. If growth has occurred, see section V., Interpretation. 
2. At 48 hours to 5 days: 
a. Re-examine aerobic plates, and simultaneously open and examine 
any anaerobic plates for that culture. 
b. Remove anaerobic plates from the anaerobic chamber immediately 
prior to examining.   
NOTE: Do not allow anaerobic plates to sit out on bench longer 
than 30 minutes.  
c. For no growth cultures: 
i. Reincubate the ANA, BA and CHOC plates for a total of 5 
days.   
ii. Discard MAC, CNA and TM plates at 72 hrs.   
iii. No additional LIS reports need to be issued until the culture 
is final at 5 days.   
iv. Continue to examine remaining plates on Days 3, 4 and 5. 
 
B. Interpretation and extent of work-up 
1. For cultures positive at 24 hours: 
a. Note the direct GS result, the source, and the patient diagnosis 
(click on the patient demographic icon on the menu bar).   
NOTE: For positive lymph node cultures, perform all work in a 
biological safety cabinet.   
b. Determine the number of organisms to workup (identification and 
susceptibility) using the Q score algorithm (pg 4).   
NOTE: Remember that the Q score algorithm is a guideline and 
may not work for every culture.  It is equally important to 
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remember that our goal is to offer accurate and timely 
information for quality patient care.   
c. Work up at 24 hr any culture growing S. aureus, -hemolytic 
streptococci, or a predominating P. aeruginosa regardless of the Q 
score. 
d. Subculture cultures that are mixed to fresh media and reincubate.   
e. The total number of organisms worked up includes both aerobic 
and anaerobic organisms; therefore, it is necessary to observe all 
plates together at  48 hrs to accurately compare predominating 
organisms.   
 NOTE: Be careful not to work up too many aerobic organisms at 
24 hours. 
2. For cultures positive at  48 hours: 
a. Recalculate the Q score (pg 4). 
NOTE: If at 24 hrs, you have begun working up aerobic 
organisms, and at 48 hrs you have a number of anaerobes, 
it is acceptable at this time, after  
bringing up on Lab Rounds, to report a mixed statement. 
b. If the number of potential pathogens exceeds the Q score, 
determine what is to be worked up by the organisms observed in 
the direct GS.   
c. If the organisms grown in culture do not correlate with those seen 
in GS, review the direct GS.  Refer to procedure 104.2.5.   
d. For suspected anaerobes: 
i. Perform a GS and save the slide for later reference.   
ii. Subculture immediately to BA, BR and CHOC.  Incubate 
as follows: 
(a) BR – anaerobic incubation.   
(b) BA – 35-37oC non-CO2. 
(c) CHOC – 35-37oC CO2. 
e. After 24-48 hrs of incubation, observe aerotolerance testing results 
using the following table.  If organism is anaerobic, send BR plate 
to MALDI for identificaton.  Use GS to assist in interpretation. 
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Aerotolerance Results: 
 Growth on 
BA 
in non-
CO2 
Growth on 
CHOC in 
CO2 
Growth 
on 
BRU in 
ANA 
Aerobe + + – 
Capnophilic 
Aerobe 
– + – 
Facultative 
Anaerobe 
+ + + 
Obligate 
Anaerobe 
– – + 
 
 3. To determine the number of organisms to workup in positive cultures, 
refer to the Q score algorithm below:   
 a. Compare the number of WBCs to the number of squamous 
epithelial cells seen in the direct GS.  The point at which the 
numbers intersect on the table is the composite quality or Q score.   
 b. Any specimen with no squamous epithelial cells is scored as 3, 
regardless of the number of WBCs.  This scoring takes into 
account the neutropenic patient who may be unable to mount an 
immune response.  
 Squamous Epithelial 
Cells 
WBC
s 
Repo
rt 
0 1-9 10-
24 
 
25 
  Non
e 
Few Mod Ma
ny 
0 None 3 0 0 0 
1-9 Few 3 0 0 0 
10-24 Mod 3 1 0 0 
 25 Many 3 2 1 0 
  Composite Q Score 
    
c. If the composite Q score equals: 
0, work up 0 organisms and use mixed statements.   
1, work up 1 organism according to GS. 
2, work up to 2 organisms according to GS.   
3, work up to 3 organisms according to GS.  
  
NOTE: This guideline may not work for every culture.  Consult rounds as needed. 
 
4. To determine the extent of workup necessary on each organism, refer to 
Table of Organism workup below.   
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Organism Quantity Workup and 
Report 
Actinomyces spp. Predominating/Pure ID 
Anaerobes Predominating/Pure ID and AST 
Arcanobacterium spp. Predominating/Pure ID 
Bacillus anthracis
1, 2
 Any Rule out/refer 
Bartonella spp. Any ID 
-hemolytic 
streptococci (large 
colony)
3
 
Any ID 
-hemolytic 
streptococci (small 
colony)  
Predominating/Pure ID and AST 
Brucella spp.
1, 2
 Any Rule out/refer 
Corynebacterium spp. Pure Consult rounds 
Enterobacteriaceae Predominating/Pure ID and AST 
Enterococcus spp. Pure 
----------------- 
All others 
ID and AST 
----------------- 
Consult rounds 
Eikenella spp. Predominating/Pure ID 
Erysipelothrix spp. Predominating/Pure ID 
Francisella spp.
1, 2
 Any Rule out/refer 
Fungus Any Consult rounds 
Haemophilus spp. Predominating/Pure ID and B-lact 
Listeria spp. Any ID and AST 
Mycobacterium spp.
1
 Any ID 
Neisseria gonorrhoeae Any ID 
Neisseria meningitidis 
1
 
Predominating/Pure ID 
NF GNRs  Predominating/Pure ID and AST 
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Nocardia spp. Any ID 
Pasteurella spp. Predominating/Pure ID 
Pseudomonas 
aeruginosa 
3
 
Predominating/Pure ID and AST 
Staphylococcus 
aureus
3, 4
 
Any ID and AST 
Staphylococcus aureus 
small colony variant 
Any If only variant, 
perform ID and 
AST.  If parent 
and variant 
present, report 
only parent ID and 
AST. 
Staphylococcus 
coagulase-negative
4
 
Predominating/Pure Consult rounds 
Staphylocuccus 
lugdunesis 
Predominating/Pure ID and AST (use 
S. aureus 
interpretation for 
oxacillin and 
cefoxitin). 
Streptococcus milleri 
group 
Predominating/Pure ID and AST 
Streptococcus 
pneumoniae 
Predominating/Pure ID and AST 
Yersenia pestis
1, 2
 Pure Rule out/refer 
Viridans streptococci Pure ID and AST 
Yeasts Predominating/Pure ID 
1
Always work in biosafety hood. 
  
2
If GS is a poorly staining GNR with pinpoint colonies at 2-4 days, 
perform all work in BSC in AFB laboratory. 
   
 Refer to manual 114 for workup of potential bioterrorism organisms.  
3
Always work up regardless of Q score. 
4
If pure, refer to procedure 105.3.1, Flow Chart II. 
 
VI. IDENTIFICATION AND SUSCEPTIBILITES 
 A. Refer to manual 105, as needed, for identification procedures.   
B. Refer to manual 106, as needed, for susceptibility testing guidelines and procedures.   
 
VII. REPORTING 
B. Report Panic Values as indicated in procedure 100.7.2.   
C. Preliminary reporting 
1. If negative, report NEGP = “No growth to date, continuing incubation.”  
2. If positive, report organism identification (descriptive or definitive) with 
quantitation.   
3. If hazy or young growth, report SCGRCURE = “Scant growth, culture 
reincubated.” 
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D. Final reporting 
1. If wound culture is negative, report NEGF = “No aerobes or anaerobes 
isolated.” 
2. If tissue culture is negative, report NEGF = “No growth after 5 days.” 
3. If positive, report: 
a. Organism identification with quantitation. 
b. Site-appropriate mixed statements with quantitation, if applicable: 
   i. MAB = “Mixed aerobic bacteria”. 
  ii. MNB = “Mixed anaerobic bacteria”. 
iii. MANB = “Mixed aerobic/anaerobic bacteria”. 
iv. MRB = “Mixed respiratory bacteria”. 
v. MIB = “Mixed intestinal bacteria”. 
vi. MXB = “Mixed bacteria, including...”. 
vii. MXFF = “Mixed fecal flora”.   
viii. MSF = “Mixed skin flora. 
ix. MUF = “Mixed urogenital flora”. 
x. MVF = “Mixed vaginal flora”. 
  NOTE: Freetext in organisms on workcard to be included 
in mixed statements.   
c. If no anaerobes are seen on culture but aerobes are reported, add 
NOANA = “No anaerobes isolated,” to the final report.   
d. If no aerobes are seen on culture but anaerobes are reported, add 
NOAER = “No aerobes isolated,” to the final report. 
 
VIII. PROCEDURE NOTES 
 A. Dialogue between the clinician or nurse and the microbiology laboratory should 
be encouraged for proper interpretation of results.   
 
 B. The results of wound cultures will only be as valuable as the quality of the 
specimen submitted, its transport, and expedient processing.   
 
 C. Reporting selected organisms in mixed cultures can lead to erroneous 
interpretation of the number and variety of infecting pathogens.   
 
E. Performance of AST is not indicated in cases of mixed microbiota indicative of 
infection of the abdominal cavity with bowel contents.  Treatment should include 
broad-spectrum coverage for normal intestinal microbiota.   
 
E. Use of the Gram stain can improve the accuracy of evaluating the importance of 
each potential pathogen.  Organisms present in the Gram stain of an appropriately 
collected specimen correlate with  105 organisms per g of tissue. 
 
F. Clinical studies have demonstrated that the microbial load in an acute wound can 
predict delayed healing or infection.  The more numerous the organisms, the more 
likely they are to be indicative of infection.   
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 G. Many wound infections are polymicrobic, and the isolation of an organism in 
culture may or may not correlate with infection of the wound.   
  
 H. The microbiologist plays a critical role in the treatment of wound infections 
because practitioners often consider the report from the laboratory as definitive 
proof of infection.  Providing inappropriate identifications and susceptibility 
results can prompt unnecessary treatment.   
 
 I. The presence of PMNs is an indication of an inflammatory or infectious process, 
while the presence of epithelial cells indicates surface contamination of the 
specimen.  Specimens containing numerous epithelial cells yield culture results of 
questionable accuracy in the diagnosis of the infectious process. 
 
 J. If a patient is immunocompromised or has poor vascular supply, inflammatory 
cells may not be present in the specimen as a guide to the extent of workup of the 
culture.   
 
 K. Low levels of organisms or fastidious organisms that grow poorly on the direct 
plates may be missed in culture.   
 
IX. REFERENCES 
A. Isenberg, Henry D.  2010.  Clinical Microbiology Procedures Handbook.  Vol. 1, pp. 
3.13.1.1-18.  ASM Press, Washington, D.C. 
 
            B.  Sharp, Susan.  1999.  Algorithms for Wound Specimens.  Clin.  
            Microbiol. Newsletter 21:14, 118-120. 
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Appendix C 
 
MALDI-TOF Protocol 
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I. PRINCIPLE 
 The Bruker MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization-Time of Flight) 
Biotyper allows fast and reliable identification of microorganisms.  Bacterial colonies are 
directly spotted onto a MALDI steel target.  An overlay of Formic Acid (for extraction) 
followed by HCCA (matrix) is applied on top of the bacteria for protection from the laser 
beam.  The steel plate is inserted in the instrument where microorganisms are identified 
by their molecular composition of proteins and peptides and are arranged in a spectrum 
with increasing mass.  This resulting characteristic peak pattern allows for reliable 
identification of microorganisms to the species level. 
 
II. SPECIMENS 
A. Bacteria - Pure organism from a 24-hr to 7-day-old culture plate submitted on 
CHOC, BAP or Brucella (Remel or PRAS). 
NOTE: No potential Bioterrorism (BT) organisms should be tested on the 
MALDI-TOF.  If Neisseira meningitidis is suspected, spot plate and overlay with 
Matrix under a Biosafety Hood.  Perform testing on the MALDI-TOF only after 
Matrix is thoroughly dry. 
B. Yeast – Pure organism from a 24-hr to 4-day-old culture plate submitted on 
Sabouraud, Chocolate or Blood agar. 
 
III. REAGENTS AND MATERIALS 
A. Bruker MALDI Biotyper Steel Target Plate. 
B. Bruker Bacterial Test Standard (BTS). 
C. Bruker HCCA (matrix). 
D. Toothpicks. 
E. Eppendorf Brand pipettes/tips (1-10 µL; 10-100 µL; 100-1000 µL). 
NOTE: Use only Eppendorf brand pipettes/tips with the Bruker Maldi-TOF.  
Other plastics may loosen and cause issues inside the mass spectrometer. 
F. MALDI Biotyper Target Worksheet (pg 7). 
G. Biological Safety Cabinet (BSC). 
H. 100% Ethanol, HPLC/MS Grade. 
I. 100% Formic Acid, HPLC/MS Grade. 
J. 100% Acetonitrile, HPLC/MS Grade.   
NOTE: Acetonitrile is highly flammable. 
K. 100% Trifluoroacetic acid, HPLC/MS Grade.   
NOTE: Trifluoroacetic acid is very corrosive.  Double nitrile gloves and eye 
protection must be worn when handling.  
L. Organic Solvent Standard Solution. 
M.       Ultra-Pure water, HPLC/MS Grade. 
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M. Bruker MALDI Biotyper Steel Target Plate. 
N. Bruker Bacterial Test Standard (BTS). 
O. Bruker HCCA (matrix). 
P. Toothpicks. 
Q. Eppendorf Brand pipettes/tips (1-10 µL; 10-100 µL; 100-1000 µL). 
NOTE: Use only Eppendorf brand pipettes/tips with the Bruker Maldi-TOF.  
Other plastics may loosen and cause issues inside the mass spectrometer. 
R. MALDI Biotyper Target Worksheet (pg 7). 
S. Biological Safety Cabinet (BSC). 
T. 100% Ethanol, HPLC/MS Grade. 
U. 100% Formic Acid, HPLC/MS Grade. 
V. 100% Acetonitrile, HPLC/MS Grade.   
NOTE: Acetonitrile is highly flammable. 
W. 100% Trifluoroacetic acid, HPLC/MS Grade.   
NOTE: Trifluoroacetic acid is very corrosive.  Double nitrile gloves and eye 
protection must be worn when handling.  
X. Organic Solvent Standard Solution. 
M.       Ultra-Pure water, HPLC/MS Grade. 
 
Y. Eppendorf 1.5 µL microfuge tubes. 
Z. Two plastic squeeze bottles (for 70% ethanol and water). 
AA. Vortex. 
BB. Microfuge tube rack. 
CC. Sharpie pen. 
DD. Microcentrifuge.  
EE. Safety glasses or face shield. 
FF. Kim Wipes 
 
IV. CALIBRATON AND QUALITY CONTROL 
A. Calibration is performed each day and with each change in the target plate.  BTS 
is used as the calibrator and calibration needs to pass for runs to be acceptable.  
Refer to section VI.D. for calibration instructions. 
 
B. QC organisms 
NOTE: Refer to procedure 110.3.4 for maintenance of MALDI QC organisms.  
QC organisms will be kept at room temperature on the MALDI bench. 
1. E. coli, ATCC 25922. 
2. S. aureus, ATCC 29213. 
3. C. albicans, ATCC 10213. 
4. Blank control (Formic Acid and Matrix). 
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NOTE: If a tube extraction is performed, select a QC organism whose 
Gram reaction resembles the organism being extracted.  Run a tube 
extraction on that QC organism. 
C. QC testing – Perform each day and with each change in target plate. 
D. QC results 
1. Expected results:  QC organism should have the correct identification with 
a score > 1.7 for bacteria and 1.5 for yeasts. 
2. Record results on QC Form (pg 8). 
3. Unacceptable results: 
a. Notify supervisor/senior technologist. 
b. Complete QC deviation. 
c.  
V. SAMPLE PREPARATION 
A. Label MALDI Target Worksheet as follows 
1. Project – Date.initials.serial number of target plate.  Run #1, e.g., 
7.16.13.KN.0056391.1. 
2. Select unused spots on plate; on worksheet label 1 spot with BTS. 
 3. Label the next 4 spots with QC organisms (E. coli, S. aureus, C. albicans, 
blank, tube extraction (if needed). 
 4. Label the next spot with 1 accession number, excluding dashes, including 
zeros: 
  a. Repeat until all accession numbers are on the worksheet. 
  b. Each isolate will have 1 single spot.   
 5. Do not remove BTS from freezer until ready to pipette. 
 
B. All samples and QC will use the Direct Colony with Formic Acid overlay first.  
Then perform tube extraction, if needed. 
1. Direct Colony with Formic Acid: 
a. Smear biological material (single colony) onto a single spot on the 
steel target plate with a toothpick.  Allow to air dry. 
b. Overlay with 1 µL of 70% formic acid and let air dry at room 
temperature. 
NOTE: For blank control, apply formic acid on spot. 
c. Overlay with 1 µL of matrix solution.  Air dry completely. 
d. Analyze on Biotyper (see section VI.) 
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  2. Formic Acid Tube Extraction: 
 NOTE: Perform tube extraction on the QC organisms that resembles 
organism being extracted.  Record on QC Sheet (pg 8). 
 a. Add 300 µL of MS Grade water to each Eppendorf microfuge 
tube. 
  b. Transfer a large, single colony of microorganism to the tube (more 
than one colony may be needed if microorganism is small; choose 
isolated colonies).  Vortex thoroughly. 
  c. Add 900 µL of 100% ethanol.  Vortex thoroughly. 
  d. Centrifuge at maximum speed for 2 minutes. 
 e. Pour off excess ethanol.  Decant remaining ethanol using a pipette; 
centrifuge for 2 minutes. 
  f. Remove all excess ethanol with fine-tipped pipette (completely 
remove all ethanol.  Let sit for 10 minutes to complete evaporation 
of any remaining ethanol. 
 g. Add 50 µL of 70% formic acid (if only a small amount of 
microorganism is available, decrease the formic acid volume to 10 
µL).  Vortex thoroughly. 
 h. Add 50 µL of 100% acetonitrile (if only a small amount of 
microorganism is available, decrease the formic acid volume to 10 
µL).  Vortex thoroughly. 
 NOTE: The volume of 70% formic acid and acetonitrile must be 
equal volumes.   
   i. Centrifuge at maximum speed for two minutes. 
   j. Pipette 1 µL of supernatant onto steel target plate; air dry. 
   k. Overlay with 1 µL of matrix; air dry (ensure target is 
completely dry before it is inserted into MBT). 
l. Analyze on the Biotyper. 
 NOTE: For any organism that is extracted, the accession # should 
be followed by “tfa” (tube formic acid), e.g., 
1319801234tfa. 
 
D. Applying BTS and Matrix 
  1. Remove a tube of reconstituted BTS from freezer and give it a 
quick spin in the microcentrifuge (2-5 seconds). 
  2. Pipette 1 µL of BTS onto one spot on the target. 
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  NOTE: Apply BTS to target plate last because it is important not 
to let BTS be exposed directly to air (protein oxidization) for a 
long period of time. 
3. Allow BTS spots to completely air dry before adding HCCA matrix. 
4. Remove HCCA matrix from RT storage drawer. 
5. Vortex the reconstituted HCCA matrix for 10 seconds. 
6. Apply 1 µL of HCCA (matrix) to each spot on target plate and allow to air 
dry. 
7. When BTS is dry, pipette 1 µL of HCCA matrix onto BTS spot. 
 
E. Open the MALDI-BIOTYPER RTC APPLICATION 
NOTE: If Windows is logged off, log on using the following: 
 User name:  Administrator 
 Password:  bruker12 
1. Click on New Classification (icon looks like a piece of paper). 
2. Name the project:  Date.Initials.target#.Bench.Run#. 
3. Click on NEW  NORMAL PROJECT  OK. 
4. Click on NEXT and maximize the screen. 
5. Highlight the spots to be tested.  Left click and drag to cover the spots  
right click  Add Analytes.  Repeat to add partial rows. 
6. Under ID, type in or scan the accession numbers (e.g., 1303304437-1).  
Press ENTER. 
7. Once the run is built, minimize RTC.  Accession numbers can be entered 
while matrix is drying. 
 
VI. MALDI-TOF BIOTYPER AND COMPUTER SOFTWARE 
A. Instrument - The Biotyper instrument should always be ON:  the system should 
have a yellow light beside warm-up and a green light beside access.  
NOTE: When the Biotyper is not in use, a target plate must be in the chamber to 
keep the vacuum stable. 
 
B. Software  
1. Open the flex control 3.3 application. 
Can load/eject using green 
button 
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2. Click on the “Load/Eject” button to move the target from the vacuum to 
the access door. 
a.  When the target is moving, there will be a yellow light beside “in 
process” on the instrument. 
 
b. When the target plate is at the access door, a green light will be 
beside “Access”. 
  3. Dust entry door surface with a Swiffer or Kimwipe. 
4. Open the door and carefully remove the old target plate and place in the 
carrying case: 
a. Carefully put the target plate to be tested in the slot.   
b. Dust O-ring with a Kimwipe. 
c. Make sure the target is laying flat.  If it is not flat, the target could 
jam the chamber.  If jammed, call the manufacturer. 
5. Click on the “Load/Eject” button.  A yellow light beside “in process” 
appears while the target is moving.   
6. When the target is ready, a green light appears beside “Access.” 
 
C. Check the vacuum 
1. Click on Status  Details  Vacuum: 
a. Make sure the vacuum status says READY and that there are green 
lights beside “Lock Rough”, “Source Rough” and “Source High.”   
b. If there is a red light, wait a few minutes and when the vacuum is 
stabilized, the lights will turn green. 
 NOTE: If the vacuum does not stabilize, check to see if there is 
dust near the access door.  If there is dust, wipe the surface 
O-ring with a Kimwipe. 
2. Close the status window (not the software).   
 
D. Calibration – perform whenever a target plate is placed in the Biotyper 
1. Click on the spots where the BTS was applied. 
2. Click on Calibrate. 
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3. When the calibration is complete, a box pops up on the screen stating that 
calibration is successful.   
4. Save the calibration once a day.  Press CTRL + Print Scrn. 
a. Open the Paint application:  Click START  PROGRAMS  
ACCESSORIES  PAINT. 
b. Click on EDIT  PASTE. 
c. To SAVE, click File  SAVE AS  DESKTOP  Calibration 
folder  use today’s date as the name  SAVE. 
d. Close the paint application. 
5. After the calibration is saved, click OK. 
6. If calibration fails: 
 a. Thaw a new BTS aliquot and repeat. 
 b. If repeat calibration is out of range: 
  (1) Reconstitute new BTS. 
  (2) Prepare new organic solvent and the fresh BTS. 
 c. If repeat calibration with new BTS fails, inform a senior 
technologist/supervisor. 
7. Minimize flex control. 
 
E. Start run 
1. Maximize RTC software. 
2. Click FINISH. 
3. Run will process. 
 
 F. When the run is complete, print the results 
  1. Click on the “View Results” icon (looks like a calculator). 
  2. Right click on the screen. 
  3. Select PRINT from the pop-up box. 
  4. Type in the number of pages to print. 
   NOTE: Only print the pages that have the identification and score. 
  5. Click on PRINT. 
  6. If yeast identifications were performed and the scores for the yeast 
spots were between 1.5 and 1.7, then manually record the yeast ID on the 
Maldi printout: 
   a. Scroll through the Maldi report looking for any yeast 
identifications that appear in red and whose first score is between 
1.5 and 1.7. 
   b. Record the identification on the Maldi sheet in the 
corresponding spot location. 
 G. When finished, close the flex control and MALDI RTC applications. 
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